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Abstract 
 
Introduction: Acute and preventive treatment of primary headache disorders is not completely 
resolved with regards to efficacy, safety, and tolerability. Hence peripheral and central 
neuromodulation can provide therapeutic alternatives in drug-resistant cases. Peripheral targets 
of neuromodulation include invasive and non-invasive neurostimulation and electrical and 
chemical nerve and ganglion blockades. 
Areas covered: A PubMed search of papers published from January 2012 to October 2018 was 
conducted. The goal of this review was to analyze the efficacy and safety of invasive 
(implantable) peripheral neurostimulation methods (the occipital nerve, the cervical branch of 
vagal nerve, the sphenopalatine ganglion) and non-invasive (transcutaneous) peripheral 
neurostimulation methods (the occipital nerve, the supraorbital nerve, and the cervical and 
auricular branches of the vagal nerve), based on the results of published clinical trials and case 
series. Acting also on the peripheral nervous system, peripheral nerve (i.e., greater occipital 
nerve) and ganglion (i.e. sphenopalatine ganglion) blockades, botulinum neurotoxin type A-
hemagglutinin complex therapies, and calcitonin gene-related peptide-related monoclonal 
antibody treatments in this patient population are also discussed. 
Expert commentary: This review summarizes the latest results on the therapeutic strategies 
acting on the periphery in primary headache disorders. These therapeutic options are minimally 
invasive or non-invasive, efficacious, safe, and well tolerated. 
 
Keywords: botulinum neurotoxin type A-hemagglutinin complex, calcitonin gene-related 
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1. Introduction 
Treating drug-resistant (a.k.a. refractory) primary headache patients represents a big challenge 
at different levels of health care from the emergency department setting to the tertiary headache 
center. By consensus, the definition of refractory is that patients do not respond to the current 
and adequate medications [1]. In this special patient population, some potential peripheral 
nervous system therapeutic options are available. The rationale for these different methods is 
not fully elucidated, but they are predominantly connected with the leading hypothesis of the 
activation and sensitization of the trigeminovascular system. 
Peripheral neuromodulatory techniques include neurostimulation methods and peripheral nerve 
or ganglion blockades. Peripheral neurostimulation in primary headache disorders can be 
devided into non-invasive (i.e., transcutaneous) and invasive (i.e., surgically implanted) 
methods. Non-invasive methods are: transcutaneous occipital nerve stimulation (ONS), 
transcutaneous supraorbital nerve stimulation (SONS; the Cefaly® device), transcutaneous 
cervical vagal nerve stimulation (VNS; the gammaCore® device), and transcutaneous auricular 
VNS (the NEMOS® device) [2], [3]. Invasive neurostimulation techniques include the 
following: implantable ONS, implantable SONS, implantable cervical VNS, and implantable 
sphenopalatine ganglion (SPG) stimulation (the Pulsante SPG Microstimulator System®). In 
pharmacoresistant migraine and trigeminal autonomic cephalalgias (TACs), both non-invasive 
and invasive peripheral neurostimulation techniques are indicated either as abortive (a.k.a. 
acute) or prophylactic (a.k.a. preventive) treatment [1]. In intractable migraine and cluster 
headache (CH), nerve and ganglion blockades, as minimally invasive procedures using chemical 
agents or radiofrequency (RF) ablation are recommended. Furthermore, in drug-refractory episodic 
(EM) or chronic migraine (CM), botulinum neurotoxin type A (BoNTA)-hemagglutinin 
complex injection and the novel parenteral calcitonin gene-related peptide (CGRP)-related 
monoclonal antibody (mAb) treatment are also applicable.  
The aim of this review is to provide a comprehensive summary of the current status of 
peripheral nervous system-targeted therapeutic strategies in patients with refractory 
primary headache disorders. 
 
2. Methods 
Papers selected for this work were searched within the PubMed database by using the keywords 
“headache”, “primary headache disorders”, “migraine”, “tension-type headache”, “trigeminal 
autonomic cephalalgias”, “CGRP monoclonal antibody”, “cluster headache”, “SUNCT”, 
“SUNA”, “SUNHA”, “hemicrania continua”, “neurostimulation”, “nerve blockade”, “occipital 
nerve stimulation”, “vagal nerve stimulation”, “supraorbital nerve stimulation”, 
“sphenopalatine ganglion stimulation”, and/or “botulinumtoxin”. Only abstracts published in 
English were considered. The literature search was conducted in October 2018. The earlies date 
of publication considered was January 2012, except for “botulinumtoxin”, where the search 
included studies from 2010. The authors overviewed clinical trials of various levels as well as 
case series, and classified and ranked the data based on the design of the research. All authors 
contributed to the literature review. 
 
3. Migraine 
Migraine is a common neurovascular disorder with high socioeconomic impact. The two form 
of EM is migraine without and with aura. CM is a subclass of migraine with a prevalence of 
8% among migraineurs and about 2% of general population [44]. It highly influences the quality 
of life of the patients, because these sufferers have at least 15 headache days per month (8 out 
of 15 days with migraine with or without aura) for at least three consecutive months [45]. 
 
3.1. Neurostimulation in migraine 
 
3.1.1. Non-invasive (i.e., transcutaneous) neurostimulation in migraine 
 
3.1.1.1.Transcutaneous ONS in migraine 
There is at present insufficient data for the usefulness of transcutaneous ONS in drug-refractory 
migraine [4] and only few studies have so far been published (Table 1 and Table 2A). 
Randomized controlled trials (RCTs) of transcutaneous ONS in EM 
A prospective RCT for EM prevention (n=110) using transcutaneous ONS at different 
frequencies (2 Hz, 10 Hz, and 2/100 Hz) showed a higher 50% responder rate in each test group 
compared to the sham group, without any serious adverse events (AEs) [5]. 
Single-center studies of transcutaneous ONS in mixed headache 
A single-center, open-label study of transcutaneous ONS in 41 drug-resistant headache patients 
(including patients with occipital neuralgia, cervicogenic headache, CH, and CM) revealed that 
the mean Visual Analogue Scale (VAS) pain score decreased from 5.9 (at baseline) to 2.2 (after 
transcutaneous ONS treatment). The response to ONS was better in the case of good or excellent 
preoperative response to transcutaneous electrical nerve stimulation (TENS) compared to those 
with only moderate preoperative response to TENS [6]. 
 
3.1.1.2.Transcutaneous SONS (the Cefaly® device) in migraine 
The Cefaly® device is a non-invasive TENS of the supraorbital branches of the trigeminal 
nerves (Table 1 and Table 3). The first evidence that TENS has beneficial effects in migraine 
and muscle contraction headache (today known as tension-type headache) comes from 1985 
[7]. The exact mechanism of its action is enigmatic; however, recent blood oxygen level-
dependent functional magnetic resonance imaging (BOLD-fMRI) data has revealed functional 
antinociceptive modulation in the perigenual part of the right anterior cingulate cortex [8]. A 
fluorodeoxyglucose positron emission tomography (FDG-PET) study revealed that SONS by 
Cefaly® device increased the activity of the limbic system, and the orbitofrontal and anterior 
cingulate cortices in EM without aura patients. These results indicate that the proposed 
mechanism of Cefaly® might be the modulation of the descending pain control system of the 
trigeminovascular nociceptor in the trigemino-cervical complex [9], [10]. 
This type of trigeminal nerve stimulation was the first to obtain the Food and Drug 
Administration’s (FDA) approval for migraine therapy [10] (Table 3). 
RCTs of transcutaneous SONS (the Cefaly® device) in EM 
The first double-blind RCT (Prevention of Migraine Using the STS Cefaly® – the PREMICE 
study) of SONS for preventive treatment in 67 non-CM patients was performed at five Belgian 
tertiery headache clinics. The results showed that during the 3-month-long study period, the 
mean number of headache days decreased significantly compared to the placebo group without 
any notable AEs. The number of monthly migraine attacks, headache days, and acute anti-
migraine drug intake were also reduced in the treatment group [11] (Table 3). A post-marketing 
retrospective survey highlighted that a high number (n=2,313) of EM patients were satisfied 
with the efficacy of Cefaly® as a prophylactic treatment and willing to purchase the device 
(54.4% of subjects). The rate of AEs was low and reversible, predominantly local paresthesia, 
and only 2% of subjects stopped the therapy due to AEs [12],[2]. A recent double-blind 
randomized sham-controlled study conducted in migraineurs with or without aura (n=106) 
revealed that a one-hour treatment session with Cefaly® significantly decreased the pain 
intensity only in migraine without aura attacks [13]. A recently published review article 
mentioned that some new studies with Cefaly® are ongoing e.g., acute treatment of EM or CM 
(double-blind RCT) and prevention of CM (open-label) [2]. An online questionnaire survey 
among 413 Cefaly® customers for migraine prevention demonstrated that 88.6% of the patients 
also used the device as an acute treatment in 71.8% of their attacks. The conclusion was that 
migraine attacks were mitigated and the device was well-tolerated during the headache phase 
[14]. 
Taken together, the Cefaly® device is effective, well tolerated, and safe, probably both as 
preventive and acute treatment in drug-resistant migraine sufferers. 
 
3.1.1.3.Transcutaneous cervical VNS (the gammaCore® device) in migraine 
VNS modulates the activation of the trigeminal nucleus caudalis (TNC) via inhibition of the 
vagal afferents to the trigemino-cervical complex (TCC) and with the excess glutamate levels 
in the TNC [15], [16], [17], [18], [19], [20]. Preclinical experiments showed that the trigeminal 
system influenced the parasympathetic system via CGRP and CGRP receptor components in 
the SPG [21]. Futhermore, experimental data indicate that the trigeminal-autonomic reflex may 
be active in migraine attacks [22]. We also highlight that VNS inhibits the cortical spreading 
depression (CSD), which is the electrophysiological correlate of migraine aura [23]. The 
orexinergic system provides a possible connection between the pathomechanism of migraine 
and CH via the dorsal vagal complex and the posterior part of the hypothalamus [24], [25], [26]. 
The first beneficial clinical experience of the effect of VNS on migraine pain came from an 
epileptic patient who received an implantable VNS [27]. There are several possibilities for the 
stimulation of the vagal nerve in primary headaches, including the non-invasive (i.e., 
transcutaneous) stimulation of the cervical or auricular branch of the vagal nerve and invasive 
(i.e., surgically implanted) VNS. The gammaCore® device uses electrical impulses to influence 
the cervical branch of the vagus nerve by transcutaneous administration [28] (Table 1 and 
Table 4). 
 
RCTs of transcutaneous VNS (the gammaCore® device) in CM 
The first prospective, multicenter, double-blind, sham-controlled pilot study (the EVENT 
study) for the prevention of CM (n=59; mean age of 39.2 years) demonstrated that at 2 months 
9.1% of the CM patients achieved more than 50% treatment response, whereas in the open-
label phase, at 8 months, this response rate elevated to 46.7%. The common AEs included eye 
twitch (7%), facial pain and numbness (10%), gastrointestinal symptoms (10%), and upper 
respiratory tract infection (10%) [29] (Table 4). 
RCTs of transcutaneous VNS (the gammaCore® device) in EM 
A randomized, multicenter, sham-controlled trial (the PRESTO study) for the acute treatment 
of EM (with or without aura; n=248) revealed an increased probability of achieving a pain-free 
state at 2 hours post-stimulation without any serious AEs. The VNS-treated group was superior 
to sham at 30 min: 12.7% versus 4.2%; at 60 min: 21.0% versus 10.0%; and at 120 min: 30.4% 
versus 19.7% [30] (Table 4). 
Open-label studies of transcutaneous VNS (the gammaCore® device) in CM 
An open-label, single-arm, multicenter study of non-invasive VNS for the acute treatment of 
high-frequency EM (n=14) and CM (n=36) revealed that at 2 hours after treatment 51.1% of 
the patients experienced a 50% or greater reduction in pain intensity. Some 35.4% of CM 
patients and 39.6% of high-frequency EM patients achived pain-free status at 1 and 2 hours, 
respectively. The observable AEs were tingling and pricking sensations at the stimulation site 
(in 67% of treated patients) [18] (Table 4). 
Open-label studies of transcutaneous VNS (the gammaCore® device) in EM 
An open-label pilot study of non-invasive VNS for the acute treatment of EM (with or without 
aura; n=30, 25 females and 5 males, median age of 39 years) revealed that 22% of the patients 
experienced beneficial effects. No serious AEs were reported, some moderate AEs were 
observed, like stiff neck, neck redness, shoulder pain or spasm, coughing, fatigue, dizziness, or 
joint pain [31] (Table 4). A preliminary open-label single-arm safety study in 9 adolescent (13-
18 years old) EM without aura patients revealed that 46.8% of their treated migraine attacks 
showed beneficial result. No device-related AEs were observed [32]. For 
menstrual/menstrually-related migraine patients (n=56), an open-label non-invasive VNS study 
as mini-prophylaxis revealed that 39% of the subjects showed 50% or more reduction in 
headache days. The number of menstrual/menstrually-related migraine days per month 
significantly decreased (from baseline 7.2 to 4.7 days at the end of the treratment). There were 
no serious AEs reported [33]. 
Single-center studies of transcutaneous VNS (the gammaCore® device) in migraine (EM and 
CM) 
A prospective, observational, single-center, cohort study of acute and preventive treatment in 
EM and CM patients revealed that pain intensity in VAS reduced in EM from 8 to 3.5, whereas 
in CM from 8 to 5. The number of headache days declined in EM from 11.3 to 5.7 and in CM 
from 18.1 to 12.1. The trial also demonstrated significant improvements in Migraine Disability 
Assessment (MIDAS), Beck Depression Inventory (BDI), and Pittsburgh Sleep Quality Index. 
No serious AEs were observed [34] (Table 4). 
 
Taken together, in drug-resistant migraine, the non-invasive stimulation of the cervical branch 
of the vagus nerve has beneficial effect and it is safe and well tolerated [35]. 
 
3.1.1.4.Transcutaneous auricular VNS (the NEMOS® device) in migraine 
The NEMOS® device is an easily applicable and portable stimulator of the auricular branch of 
the vagus nerve. The ear electrode is similar to a hearing aid and the stimulator is hand-held [2]. 
The proposed pathomechanism of auricular VNS is that it may stimulate the thick myelinated 
fibers of the auricular branch of the vagus nerve, which results in the activation of the nucleus 
of the solitary tract [36], [37]. 
Single-center studies of transcutaneous VNS (the NEMOS® device) in CM 
A randomized, parallel-group (1 Hz versus 25 Hz) , monocentric, double-blind, controlled trial 
with 46 CM patients revealed that in the 1 Hz group 29.4% of the patients had 50% or greater 
reduction in headache days, versus in the 25 Hz group it was only 13.3%. The Headache Impact 
Test (HIT) and the MIDAS scores were significantly improved in both groups without 
differences. The treatment-related AEs appeared at the stimulation site, like mild or moderate 
pain, paresthesia, pruritus, erythema, ulcer, or scab [36] (Table 1 and Table 4). 
 
3.1.2. Invasive neurostimulation in migraine 
 
3.1.2.1. Implantable ONS in migraine 
The pathomechanism of ONS in migraine is unclear, with both central and peripheral effects 
being possibly involved [38], [39]. The anatomical background for this technique in migraine 
and TACs is that in the TCC, the second-order nociceptive neuron has a convergent synapsis 
from the trigeminal (i.e., meningeal) part and from the spinal region (i.e., the central branch of 
the cervical 2 segment) [40], [41], [42]. The other possibilities point to the activation of afferent 
A-beta fibers and the modulation of the descending supraspinal pathways from the 
periaqueductal grey matter (PAG) and the rostral ventromedial medulla [43].  
 
RCTs of implantable ONS in CM 
A long-term (52-week) RCT demonstrated that surgically-implanted ONS significantly reduced 
the number of headache days by 7.7(±8.7) days in intractable CM patients (n=125) and by 
6.7(±8.4) days in the intent-to-treat (ITT) analyses of all patients (n=157) [18]. In this study, 
65.4% of the ITT population reported excellent or good headache relief. The MIDAS scores 
were also reduced and more than half of CM patients were satisfied with this method. Lead 
migration  was the leading AE in the hardware-related category (13.9%), whereas persistent 
pain and/or numbness was the leading AE among biological events (18.2%) [46] (Table 1 and 
Table 2A). Another RCT of ONS revealed that suprathreshold stimulation evoked better pain 
relief than subthreshold stimulation (1.98(±1.56) versus 5.65(±2.11)) in 15 CM patients. No 
changes in Short-Form-36 (SF-36) were reported. No serious AEs were detected and no 
technical malfunction was presented [47]. An RCT from 2012 revealed that ONS did not meet 
the primary endpoint (at least 50% reduction in main daily headache intensity) in a large CM 
patient group (active n=105; sham n=52); however, there was a sifgnificant difference in the 
percentage of patients who showed 30% pain reduction, and there were also significant 
differences in the reduction of the number of headache days and in migraine-related disability 
compared to the sham-treated group. The most frequent biological AE was persistent pain 
and/or paresthesia at the implant site (13.1% in active group versus 8.4% in control group). The 
most common hardware-related AE was lead migration (14% in active group versus 4.7% in 
control group) [48]. 
Open-label studies of implantable ONS in CM 
A prospective, long-term (7-year), open-label, uncontrolled, observational ONS study in 37 
refractory CM patients revealed that pain, based on the VAS evaluation, decreased by 4.9±2.0 
points. Systemic AEs were not observed [49] (Table 2A). An open-label, prospective, cohort 
study showed that 28.5% of 35 refractory CM patients showed 50% or greater reduction in the 
daily attack frequency or pain severity. AEs were not mentioned [50]. 
Cross-over studies of implantable ONS in CM 
A prospective, randomized, cross-over study with ONS showed 54-60% reduction in 
“Stimulation ON” compared to “Stimulation OFF”, both in the number and severity of headache 
attacks in CM. Only a few AEs were reported (2 infections and 3 lead migrations). The 
limitations of this study was the single center, the small number (n=34) of patients, and the 
missing control group [51] (Table 2A). 
Single-center studies of implantable ONS in CM 
A single-center (institutional) experience with combined implantable ONS and SONS revealed 
50% or greater decrease in pain severity in 71% of the CM patients (n=14). Fifty percent of the 
patients experienced resolution of migraine-associated symptoms. The main AE was lead 
migration (42.8%) [52] (Table 2A). A long-term (from 5 to 80 months) functional outcome 
dual implantable ONS and implantable SONS study revealed that 8 out of 16 CM patients had 
a positive response defined as more than 50% of improvement in headache, quality of life, and 
functional outcome scores MIDAS and BDI. The main AEs included lead migration (42.8%), 
supraorbital lead allodynia (21.4%), and infection (14.2%), with a consequent high reoperation 
rate (35.7%) [53]. A long-term (6-year) retrospective study (carried out in two large tertiary 
referral centers) revealed that 53% of refractory CM patients (n=25) reported 50% or greater 
reduction in headache intensity and/or frequency at long-term follow-up. This study included 
refractory occipital neuralgia patients as well (n=3), who reported more than 50% reduction in 
pain intensity at 28-31 months. The most frequent AE was lead displacement [54]. An 
observational, single-center experience study revealed an improvement in pain intensity by 
numeric rating scale (NRS) in CM patients at the 3-month and 12-month follow-up (NRS at 
baseline: 9.8(±0.7); at 3 months 5.0(±1.6); at 12 months: 5.7(±2.6)). Lead migration was the 
most common side effect [55]. 
 
Overall, the application of implantable ONS represents a promising therapeutic option in 
refractory CM cases. 
 
3.1.2.2. Implantable cervical VNS in migraine 
Retrospective studies of implantable VNS in epileptic patients with headache 
In the time period from 2012 to the present, a RCT with implantable VNS in purely primary 
headache disorder patients has not been published, in consistence with a recent review in the 
field [56]. A large (n=325) retrospective clinical study demonstrated that implantable VNS had 
beneficial effects on daily headache/migraine intensity (VAS=5.4 in the VNS group versus 7.8 
in the group on best medical treatment) and affective/cognitive pain perception (21 in the VNS 
group versus 16 in the group on best medical treatment) in patients with drug-resistant focal 
epilepsy [57] (Table 4). 
 
3.2. Nerve or ganglion blockades in migraine 
 
3.2.1. GON blockade in migraine 
RCTs of GON blockade with chemical agents in CM 
A placebo-controlled study of bilateral GON blockade (with 1.5 mL of 0.5% bupivacaine 
diluted in 1 mL of saline) in 44 CM patients revealed significantly decreased headache days 
from the baseline to third month (21.0 versus 6.3 days) compared to placebo (i.e., saline) 
treatment (20.9 versus 19.1 days). The pain intensity decreased from 8.9 to 6.3 in the treatment 
group, whereas in the placebo group from 8.7 to 8.6. No serious AEs were observed, only local 
pain at the site of injection, vertigo, and nausea occured [58] (Table 2B). A short-term (one-
week) RCT in 36 CM patients demonstrated that bilateral GON blockade with bupivacaine 
(with 2 mL of 0.5% bupivacaine) was effective (i.e., number of headache days of any pain 
intensity decreased from 4.9 to 3.4 in the treated group). This study also reported that the 
pressure pain thresholds increased after the blockade and decreased after placebo. Only few 
AEs were reported, including presyncope and transient stinging sensation at the puncture site 
[59]. A prospective, randomized, placebo-controlled, double-blind pilot study of ultrasound-
guided unilateral GON blockade (with 1.5 mL of 0.5% bupivacaine) in refractory CM without 
aura patients (n=32) revealed that pain intensity decreased from VAS=3.93 (pre-injection) to 
VAS=1.55 (post-injection). The ultrasound-guided technique enabled a more accurate 
localization of the nerve. No serious AE was observed, only one patient suffered vaso-vagal 
syncope [60]. A RCT of GON blockade in CM patients (n= 84) using 1.5 mL of 0.5% 
bupivacaine diluted in 1 mL of saline (four times once per week) demonstrated that the number 
of headache days decreased from 18.1 (at baseline) to 8.8 (at 1 month), whereas the VAS score 
decreased from 8.4 to 2.1. The observed AEs were local pain at the site of injection and vertigo 
[61]. A multicenter, randomized, double-blind, comparative-effectiveness study (pulsed RF 
versus 2.75 mL injection containing 1 mL of 0.5% bupivacaine, 1 mL of 2% lidocaine, and 0.75 
mL of 40 mg/mL depomethylprednisolone) including 81 participants with occipital neuralgia 
or migraine (EM and CM) with occipital nerve tenderness revealed a greater pain relief in the 
pulsed RF group compared to the steroid injection group; without any serious associated AEs 
[62]. 
RCTs of GON blockade with chemical agents in mixed or unspecified migraine 
An RCT of GON blockade using 2.5 mL of 0.5% bupivacaine plus 0.5 mL (20 mg) of 
methylprednisolone in episodic and chronic migraineurs (n=70; between 18-75 years) for short-
term preventive treatment revealed no difference in at least 50% reduction in the headache day 
frequency in active and placebo groups. The main AE was injection site pain (12% of the study 
subjects) [63] (Table 2B). A RCT conducted to compare the preventive effect of GON blockade 
with 1.0 mL of lidocaine 2% plus 0.5 mL of saline versus 1.0 mL of 2% lidocaine plus 0.5 mL 
of triamcinolone in migraine patients (n=24 versus 24) demonstrated efficacy for both groups 
in terms of pain severity, pain frequency, and analgesic use at 2, 4, and 8 weeks post-treatment; 
however, no difference was revealed between the therapies. No serious AEs were observed in 
either group [64]. A prospective RCT conducted in an emergency department in patients with 
acute migraine attack (n=60) demonstrated that GON blockade (1 mL of 0.5% bupivacaine plus 
1 mL of normal saline) was superior to placebo (2 mL of normal saline; pain scale score: from 
9 to 1 versus from 8 to 3 at 45 minutes after the injection). The GON blockade group did not 
differ from the IV dexketoprofen (50 mg) and IV metoclopramide (10 mg) groups at 45 minutes 
after treatment. No serious AEs were detected [65]. 
Open-label studies of GON blockade with chemical agents in EM 
An open-label study that compared purely GON blockade with bupivacaine (2 mL; 0.25%) 
versus GON blockade plus prophylactic medication (amitriptyline 25 mg/day, topiramate 100 
mg/day, or venlafaxine 150 mg/day) in migraineurs without aura showed significant 
improvement in headache frequency and severity in both groups, but there was no difference 
between the two groups. The attack frequency decreased from 15.73 (at baseline) to 4.52 (at 
month 3) in the GON blockade group versus from 13.76 to 3.28 in the GON blockade + 
prophylactic medication group, whereas headache severity was reduced from 8.26 to 5.16 in 
the GON blockade group versus from 8.80 to 5.96 in the GON blockade + prophylactic 
medication group. There were no serious AEs reported [66] (Table 2B). An open-label clinical 
trial of bilateral GON blockade with bupivacaine (2 mL, 0.5%) for the acute treatment of 
migraine patients with prolonged or persistent aura (n=18 patients and 22 episodes with aura) 
revealed that complete response without early recurrence was achieved in 50% (n=11) and with 
24-hour recurrence in 9.1%, (n=2) of the cases, whereas partial (greater than 50%) improvement 
was achieved in 27.3% (n=6) of the cases. No serious AEs were reported [62]. 
Open-label studies of GON blockade with chemical agents in CM 
A retrospective, open-label trial comparing unilateral and bilateral GON blockade using 1.5 mL 
of 0.5% bupivacaine plus 1 mL of saline in CM patients (n=41; 23 unilateral and 18 bilateral) 
demonstrated no difference between the two groups regarding the frequency, severity, or 
duration of headache at 3 months post-treatment. Bilateral application was not superior to the 
unilateral one. No serious AEs were found [67]. 
Cohort studies of GON blockade with chemical agents in EM 
A large retrospective cohort study of GON blockade with bupivacaine (6.3 mL, 0.25%; 2.5 mL, 
0.5%) and/or lidocaine (2.4 mL, 1%) used for the acute treatment of migraine headache reported 
an 50% or greater pain reduction in 58% of the patients (n=562; 423 women and 139 men; mean 
age of 58.6 years). Only a few AEs occurred, such as vasovagal symptoms and burning 
sensation at the injection site [68]. 
 
Overall, GON chemical blockade is a simple, applicable, efficacious, safe, well-tolerated, and 
cost-effective therapeutic option in drug-resistant migraine [69], [70]. Treatment-related AEs 
are mild and of low frequency (Table 2B). 
 
3.2.2. SPG blockade (with chemical agents) in migraine 
The hypothesized mechanism of SPG modulation in migraine is the alteration of sensory 
processing in the TCC [71],[72]. The modulation of SPG function, e.g., by means of chemical 
block, neurolysis, RF ablation, or neurostimulation in primary headache patients has shown 
some beneficial effects [3]. SPG stimulation is a minimally invasive method: the electrode, 
which has a wireless remote-controlled system (the Pulsante SPG Microstimulator System®), 
is implanted transorally into the pterygopalatine fossa [2] (Table 1 and Table 5). 
RCTs of SPG blockade with chemical agents in CM 
A double-blind, parallel-arm, placebo-controlled, randomized pilot study showed that in 41 CM 
patients, bupivacaine (0.5%) versus saline repetitive injection into the SPG with Tx360® device 
(twice a week for 6 weeks) demonstrated significantly decreased headache intensity (NRS 
scores: 4.20 versus 2.85 at 24 hours post-treatment). The bubivacaine study group was 
associated with a reduction in acute medication use and an improved quality of life. The most 
common AEs were the following: lacrimation (30%), bad taste (26%), mouth numbness (22%), 
and nasal irritation (15%) [73] (Table 5). The follow-up of the above trial, which was a long-
term (6-month-long), double-blind, parallel-arm, placebo-controlled, randomized pilot study, 
revealed that the number of headache days decreased from 23.15 (at baseline) to 17.44 (at 1 
month post-treatment). There was a statistical difference at 1 month and 6 months. The frequent 
AEs were taste disturbances, lacrimation, and oral numbness [74]. 
Open-label studies of SPG blockade with chemical agents in migraine 
A prospective, open-label, uncontrolled study in 10 intractable CM patients was performed with 
bilateral percutaneous infrazygomatic administration of BoNTA-hemagglutinin complex (total 
dose of 50 IU) in patients under local anesthesia using a novel surgical navigation device 
(MultiGuide® device). The efficacy outcome was favorable: 8 out of 10 CM patients 
experienced a 50% or greater reduction in the number of moderate and severe headache days 
compared to baseline. All 10 patients experienced different AEs, incluidng pain, swelling and 
numbness (face, cheek), and jaw problem, none of them were serious [75] (Table 5). In a 
retrospective, open-label, uncontrolled SPG blockade trial in 55 migraine patients who received 
2 ml of 2% lidocaine in each nostril by a Sphenocath® device for acute treatment, 78.2% of the 
patients were headache-free at 2 hours post-treatment and only few AEs were reported [76]. 
 
Overall, SPG blockade with chemical agents (i.e., bupivacaine or BoNTA-hemagglutinin 
complex) may have beneficial effects in medically refractory migraine patients. 
 
3.3. BoNTA-hemagglutinin complex injection therapy in migraine 
BoNTA is a purified neurotoxin produced by Clostridium botulinum bacteria. The effect of 
BoNTA in the nervous system is the specific cleavage of synaptosomal membrane-associated 
protein 25 kDa (SNAP-25) [77], [78], [79]. In clinical testing, it has been revealed that BoNTA 
diminished the interictal CGRP serum level in CM patients and was also able to reduce central 
sensitization [80], [81], [82], [44]. The non-toxic components of the two forms of BoNTA 
(onabotulinum toxin A and abobotulinumtoxin A) each include a hemagglutinin [79]. Two 
RCTs, the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) 1 and 2, 
demonstrated that BoNTA-hemagglutinin complex reduced the monthly headache days in CM 
patients [83], [84]. The recommended injection fixed-sites are frontal, temporal, occipital, and 
neck muscles, and the recommended fixed-doses are totally 155-195 units (U)/cycle (one cycle 
is 12 weeks) [85], [86], [87], [44]. The latest Cochrane Database meta-analysis, which includes 
28 trials (4190 participants) – the longest treatment duration was three cycles of injections – 
concluded that BoNTA-hemagglutinin complex treatment in CM reduced the number of 
migraine days per month by 2 days compared with placebo at 24 weeks (-8.4 days on BoNTA-
hemagglutinin complex group; versus -6.6 days in placebo group), and no serious AEs were 
reported [88]. BoNTA-hemagglutinin complex is a medication approved by the FDA for the 
prevention of CM, and it is effective and safe, both in RCTs and in real-life studies [89], [90]. 
 
3.4. CGRP- or CGRP receptor-targeted monoclonal antibody treatment in migraine 
In a classical clinical experiment, Edvinsson and his co-workers elegantly demonstrated the 
function of CGRP during migraine attack [91], [92]. The pathomechanism of migraine is 
unknown, but the activation and sensitization of the trigemino-vascular system via 
neuropeptides like CGRP and pituitary adenylate cyclase-activating polypeptide (PACAP) have 
crucial roles [93], [94], [95], [96], [97,98]. The center of the trigeminovascular system is the 
trigeminal ganglion, which has numerous CGRP-like immunopositive nerve cells and it is not 
protected by the blood-brain barrier; therefore, it can be an ideal peripheral target for 
monoclonal antibodies (mAbs) in migraine therapy [99], [100], [101], [102], [103]. New 
genetic engineering techniques have opened up the possibility of developing fully humanized 
mAbs targeting CGRP and CGRP receptors [104], [93]. The recent overviews summarized the 
efficacy outcome (50% or greater reduction in migraine days) of CGRP-related mAbs in EM 
and CM patients. The route of administration is parenteral (subcutaneous or intravenous). The 
CGRP receptor-targeted erenumab (AMG334) reached 46% versus placebo, while CGRP-
targeted eptinezumab (ALD403) 61%, galcanezumab (LY2951742) 63% and fremanezumab 
(TEV48125) 53% versus placebo in EM patients. The most frequent AE was upper respiratory 
tract infection, and there were no serious AEs [93], [103]. Eptinezumab treatment in CM 
patients achieved a significant reduction in monthly migraine days compared to placebo 
(PROMISE 2 study) [105]. In fremanezumab-treated CM patients, the number of headache 
hours during study weeks 9-12 was significantly reduced compared to that in the placebo group. 
In the HALO CM fremanezumab trial, a higher rate of patients associated with a reduction of 
at least 50% in the average number of headache days per month was observed in the treated 
group compared to the placebo group. Galcanezumab treatment in CM patients (REGAIN trial) 
resulted in a significant decrease in the number of monthly headache days compared to controls 
[105]. 
 
4. Cluster headache 
CH is one of the TACs. Typical features of CH attacks are strictly unilateral, very severe pain 
in orbital, supraorbital, and/or temporal areas. The head pain lasts 15-180 minutes and occurs 
from once every other day to eight times a day, and is typically associated with ipsilateral 
autonomic symptoms, such as conjunctival injection, lacrimation, nasal congestion, rhinorrhoea, 
forehead and facial sweating, miosis and/or ptosis, and/or eyelid oedema. Restlessness or 
agitation may be present [45]. Its two main forms are episodic CH (ECH) and chronic CH 
(CCH). 
 
4.1. Neurostimulation in CH 
 
4.1.1. Non-invasive neurostimulation in CH 
 
4.1.1.1. Transcutaneous cervical VNS (the gammaCore® device) in CH 
The rationale of VNS in CH is based on the observation that the strong parasympathetic 
activation during CH attack is linked to the anatomical connection of the trigeminal system with 
the autonomic nervous system through the TCC. The superior salivatory nucleus 
(parasympathetic nucleus of the facial nerve) receives synaptic input from the central branch of 
the trigeminal ganglion. The consequence of its activation is the excitation of the SPG, which 
results in the release of parasympathetic neuropeptides (such as vasoactive intestinal 
polypeptide) to the pericranial vasculature [102],[106]. 
RCTs of transcutaneous VNS (the gammaCore® device) in CH 
A prospective, open-label RCT (the PREVA study) of transcutaneous VNS in CCH patients 
(n=97) reported that the number of CH attacks per week significantly decreased compared to 
the control group (5.9 versus 2.1). Around 40% of the treated patients showed a response rate 
of 50% or greater. The most common AEs were headache (8%), dizziness (6%), oropharyngeal 
pain (6%), and neck pain (6%) [17] (Table 4). A randomized, double-blind, sham-controlled 
study of VNS for the acute treatment of ECH and CCH patients (n=60;the ACT1 study, 
conducted in the USA) revealed that only the ECH but not CCH patients experienced beneficial 
effects (ECH: 34.2% versus 10.6%; CCH: 13.6% versus 23.1%). The device-related AEs were 
burning, tingling, soreness, stinging at the application site (2.7%), and lip or facial drooping, 
pulling, or twitching (11.0%) [107]. A new extended RCT, the ACT2 study, in an European 
setting drew similar results. The total cohort of 92 ECH and CCH patients demonstrated no 
significant difference between non-invasive VNS (14%) and placebo stimulation (12%). The 
VNS treatment was superior to sham in ECH but not in CCH [108]. Regarding the economic 
aspect, the cost-effectiveness of the non-invasive VNS (the gammaCore® device) for the acute 
treatment of both ECH and CCH was superior to standard of care [109], [110]. 
Overall, in refractory CH, transcutaneous cervical VNS showed promising effect without any 
serious AE. 
 
4.1.2. Invasive neurostimulation in CH 
 
4.1.2.1. Implantable ONS in CH 
The central effect of implantable ONS is based on its potential to modulate the pain matrix, 
hence returning the associated hypermetabolism to a normal level, as measured by FDG-PET 
in CCH patients [111]. Evidence indicates the metabolic activation of different anatomical 
regions of the pain matrix in various primary headache disorders [40], [111], [112]. We 
underline the observation, however, that in CCH patients, ONS normalized the alteration in 
metabolism in each examined brain regions except the ipsilateral hypothalamus [111], the 
activation of which may have a crucial role in the generation of a CH attack [113]. In the CCH 
patients, after the cessation of ONS, attack recurrence is high, probably due to the lack of 
modulation of the activation of the hypothalamus [111], [1], [40]. 
RCTs of implantable ONS in CH and mixed headache 
The ICON study (the first blinded trial of peripheral pain neuromodulation in medically 
intractable CCH), which is still ongoing, will present some data from a double-blind set-up [38], 
[114], [43]. (Table 2A). A long-term (8.5-year) RCT indicated that migraine, CH, and 
miscellaneous headache patients (n=29) responded well to ONS. Headache frequency was 
decreased by 18%, severity by 27%, and MIDAS by 50%. In CCH patients, four of five patients 
reported good effects. With regards to AEs, lead revision was the most common one (58%) 
[115]. 
Open-label studies of implantable ONS in CH 
An open-label prospective cohort study of 33 CCH patients showed the beneficial effect of the 
method (54.5% of the patients reached 50% or more reduction in attack frequency) [50].  
A long-term (median follow-up of 6.1 years) monocentric open-label ONS study demonstrated 
that 66.7% of the 35 drug-resistant CCH patients presented 50% or greater reduction in 
headache number per day. The most frequent AEs were battery depletion (70%) and electrode 
migration (20%) [116] (Table 2A).  
Single-center studies of implantable ONS in CH 
The results of the prospective single-center but long-term (mean follow-up 20 months) study in 
intractable CCH or migraine showed high response rates (89% at short-term and 78% at long-
term) to bilateral ONS. However, it appears to be a costly therapy (mean treatment cost is 
28,186 EURO per case) [117] (Table 2A). Another single-center, long-term follow-up (1-8-
year) study revealed that 8 out of 16 drug-resistant CCH patients became asymptomatic with 
bilateral ONS, whereas 2 patients changed from the chronic to episodic subtype, and 4 out of 
16 patients showed more than 50% improvement in the reduction of the number of headache 
attacks. The frequent AEs were electrode migration, battery replacement, and local infection 
[118]. 
Observational studies of implantable ONS in CH 
A large, observational, prospective study in medically intractable CCH patients (n=67) revealed 
that 59% of the patients reached a decrease in attack frequency of 50% or greater by ONS. A 
high percentage (70%) of the patients responded to the treatment. Moreover, as regards the 
secondary endpoints, the HIT-6, the MIDAS, and the Hospital Anxiety Depression Scale scores 
were significantly improved, and the use of prophylactic drug treatment decreased in 40% of 
patients. Only minor AEs were observed in 33% of the treated group [119] (Table 2A). 
 
Overall, the results of ONS treatment in drug-resistant CCH patients demonstrated that the 
majority (i.e., two-third) of the subjects responded well to the treatment (50% or greater 
improvement in frequency and/or intensity); however, it is noteworthy that these were only 
observational studies [38], [120]. A recent systematic review with meta-analysis concluded that 
the number of RCTs of ONS for intractable primary headache disorders is extremely low and 
further research and high-level studies are needed [121]. ONS is an effective treatment 
compared to a placebo treatment. It is a promisingly useful but invasive and costly therapeutic 
option for drug-refractory primary headache disorders [50], [121]. The common and frequent 
side effects of ONS are lead migration and local inflammation [40], [43]. The currently 
available study results suggest that ONS is a valuable procedure with significant hardware- and 
non-hardware-related AEs even in experienced hands. In the near future, large, rigorous and 
well-designed high-level RCTs are needed. 
 
4.1.2.2. Implantable SPG stimulation (the Pulsante SPG Microstimulator System®) in CH 
Parasympathetic storming (lacrimation, rhinorrhoea, nasal congestion, and eyelid edema) is 
associated with trigemino-autonomic headache attacks (such as in CH) and some migraine 
attacks [72]. The anatomical center of this phenomenon is the SPG, which has connections to 
the trigemino-vascular system via the trigemino-parasympathetic reflex and also to the 
hypothalamus [122], [123], [2], [124]. Despite the significant clinical parasympathetic 
activation and sympathetic dysfunction (ie., ptosis and miosis), the origin of the pain and the 
connection with the SPG are not well characterized [123]. 
RCTs of SPG electrical stimulation in CH 
The first European clinical trial of acute treatment for CCH patients (n=32; the PATHWAY 
CH-I study) demonstrated that 25% of the patients achieved more than 50% pain relief, and 
36% of the CCH patients reported a more than 50% reduction in attack frequency, whereas 7% 
experienced both [125]. The reported AEs were sensory disturbances (hypesthesia, paresthesia, 
dysesthesia, and allodynia) in the 81% of the patients, and pain affecting the face, 
temporomandibular joint, nose, or incision site in 38% of the patients [125] (Table 5). A long-
term (24-month), open-label follow-up of the PATHWAY CH-I study regarding attack 
remission revealed that 30% of the CCH patients (n=33) experienced at least one episode of 
complete attack remission. The pain-free period was at least one month. No serious AE was 
mentioned [122]. The evaluation of the long-term effectiveness in the same study cohort 
demonstrated that 45% of the CCH patients were acute responders and 33% of them was 
frequency responder; this yield a total responder rate of 61% [126]. The PATHWAY R-1 
registry (open-label, prospective, post-marketing) study of SPG stimulation in ECH (n=7) and 
CCH (n=78) patients revealed that 68% of all patients were responders. In CCH patients, 65% 
of the patients showed 50% or greater response, either in term of the reduction in the attack 
intensity or attack frequency. In ECH patients, 71.4% (n=5/7) responded well to the SPG 
neurostimulation therapy in terms of frequency; however, only 28.6% (n=2/7) experienced 
acute response. It was reported that 59% and 67% of all patients were HIT-6 and SF-36 
responders, respectively. Regarding the AEs, 73% of all patients reported postoperative 
sequela, which were mild-to-moderate and resolved within 2-3 months [127]. 
Overall, SPG neurostimulation is a promising therapeutic option for intractable CH, mainly in 
its chronic form, with limitations due to its invasive nature. 
 
4.2. Nerve or ganglion blockades in CH 
 
4.2.1. GON blockade in CH 
 
RCTs of GON blockade (with chemical agents) in CH 
A double-blind, placebo-controlled, ipsilateral GON blockade trial was conducted with a 
mixture of rapid-acting salt of betamethasone (disodium phosphate, 5.26 mg) and a long-acting 
salt of bethametasone (dipropionate 12.46 mg) and 0.5 mL of 2% xylocaine in ECH (n=16) and 
CCH (n=7) patients. A single dose of GON blockade completely diminished the CH attacks in 
more than 80% of CH patients in the verum group. The most common AE was transient pain at 
the injection site [128]. 
Open-label studies of GON blockade (with chemical agents) in CCH 
An open-label observational case series (n=10) GON blockade study using high-volume (9 mL) 
lidocaine and triamcinolone (1 mL) in CCH patients demonstrated that all patients had complete 
pain relief for an average of 65.1 days post-injection. Smoking history did not alter the treatment 
response. No serious AEs were reported except for one patient who developed avascular 
necrosis of the hip [129] (Table 2B). A prospective open-label study with unilateral GON 
blockade (with methylprednisolone) in CCH patients (n=83) demonstrated that 57% of the 
patients reached at least 50% pain relief (42% of them achieved complete response) after the 
first GON blockade. Regarding AEs, 34% of the sample population reported tenderness at the 
injection site, neck stiffness, or dizziness [130]. 
Single-center studies of GON blockade (with chemical agents) in CH 
A retrospective comparative single-center study for short-term prophylaxis of ECH and CCH 
comparing GON blockade with methylprednisolone to an oral steroid (prednisone or 
dexamethasone) revealed that 82.7% of the oral steroid encounters (n=81) compared to 64.4% 
of GON injection encounters (n=59) experienced complete or partial treatment response. No 
AEs were recorded [131]. 
Retrospective studies of GON blockade (with chemical agents) in CH 
A retrospective analysis with unilateral or bilateral GON blockade (121 injections in 60 ECH 
or CCH patients with betamethasone) revealed that after the first blockade 64.8% of the patients 
showed favorable treatment response. The reported AEs were local pain and steroid-related 
symptoms (e.g., facial oedema, sleeping disorders, or acne), bradycardia, and syncope [132]. 
Prospective studies of GON blockade (with chemical agents) in CH 
A prospective observational study with single GON blockade (triamcinolone plus bupivacaine) 
in ECH (n=61) and CCH (n=40) patients revealed that 83.2% of the patients had complete or 
partial response. No serious AEs occurred, only tiredness was reported [133]. 
Overall, the GON chemical blockade showed beneficial effect and it was well tolerated in the 
drug-refractory CH study population [134], [135]. It can be performed on an outpatient basis 
[43]. 
 
4.2.2. SPG blockade in CH 
Open-label studies of SPG blockade (with RF ablation) in CH 
A prospective, open-label, follow-up (12-30 months) study revealed that 11 out of 13 ECH 
patients and 1 out of 3 CCH patients experienced a pain-free state within an average of 6.3 days 
following the computerized tomography-guided pulsed RF treatment, with no serious AEs 
reported [136] (Table 5). 
Case series of SPG blockade (with RF ablation) in CCH 
In a case series, 2 out of 3 CCH patients reported no pain relief after infrazygomatically pulsed 
RF treatment. After this unsuccessful procedure, the patients underwent continuous RF 
treatment with corticosteroid (40 mg of methylprednisolone) and a local anesthetic (1 ml of 1% 
lidocaine) injection into the pterygopalatine fossa, which resulted in complete pain relief in all 
of the patients [137] (Table 5). 
Open-label studies of SPG blockade (with chemical agents) in CH 
A prospective, open-label, uncontrolled pilot study with a follow-up of 24 weeks in 10 CCH 
patients demonstrated that a single symptomatic side transnasal injection of 
onabotulinumtoxinA (25 IU or 50 IU) under generalized anesthesia resulted in at least 50% 
reduction in attack frequency compared to the baseline in 50% of the patients. Regarding the 
safety outcome, 70% of the headache patients experienced AEs, including accomodation 
problems and epistaxis (anterior and posterior) [138] (Table 5). A retrospective, single-center, 
open-label study in CH patients (n=14) revealed that percutaneous neurolysis with 1 ml absolute 
alcohol under local anesthesia and computer tomography guidance with an infra- or 
suprazygomatic approach was beneficial, as there was 50% or greater pain relief in 76.5% of 
the patients without any serious AEs [139]. 
 
Overall, in medically refractory CH patients, SPG blockade (with RF ablation or chemical 
agents) is effective, safe, and well tolerated. 
 
4.3. BoNTA-hemagglutinin complex injection therapy in CH 
A number of clinical trials using BoNTA-hemagglutinin complex as prophylaxis in CCH 
patients have been reported [140]; however, only a single trial followed the PREEMPT study 
protocol until now [141]. In this open-label, non-randomized, single-center study, a greater than 
50% reduction in headache minutes was reached in 58.8% of the refractory CCH patients. The 
pain intensity was also significantly reduced in this patient population [141]. 
 
5. TACs other than CH 
The TACs share the clinical features of unilateral headache and cranial autonomic features, 
which are ipsilateral to the headache [45]. Short-lasting unilateral neuralgiform headache 
attacks (SUNHA) are moderate or severe in intensity, strictly unilateral, lasting seconds to 
minutes, occurring at least once a day and usually associated with prominent lacrimation and 
redness of the ipsilateral eye [45]. Its two subtypes are short-lasting unilateral neuralgiform 
headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral 
neuralgiform headache attacks with cranial autonomic symptoms (SUNA), both of them can be 
episodic or chronic [45]. These are rare disorders, the prevalence of SUNCT is 6.6/100.000 
persons and SUNA five times less frequent [144]. Hemicrania continua (HC), either remitting 
or unremitting subtypes, is a persistent, strictly unilateral pain, associated with ipsilateral 
autonomic features and/or with restlessness or agitation. HC responds exclusively to 
indomethacin [45], [147]. 
 
5.1. Non-invasive (i.e., transcutaneous) cervical VNS (the gammaCore® device) in TACs 
other than CH 
Open-label studies of transcutaneous cervical VNS in mixed headache (CM and TACs) 
A real-world, open-label, prospective, clinical audit evaluated 41 refractory chronic primary 
headache patients after non-invasive cervical VNS for preventive and abortive treatment. The 
beneficial effects of VNS in these patients were surprisingly low. In CM patients only 2 out of 
23, in CCH 1 out of 12, in HC 2 out of 4, and none of the SUNA patients (n=2) reported a 
beneficial effect, which was defined as an at least 30% reduction of headache days/episodes. 
There were no serious AEs observed. Otherwise, patients reported transient hoarseness/sore 
throat, red skin on the face and on the neck, increased frequency of bowel movements/flatus, 
and facial twitching [142] (Table 4). 
Single-center studies of transcutaneous cervical VNS in TACs other than CH 
In rare indomethacin-sensitive TACs such as HC (n=9) and paroxysmal hemicrania (n=6), a 
monocentric clinical study demonstrated that in the indomethacin non-tolerant patients the 
transcutaneous cervical VNS, as an alternative or adjunctive therapy, showed beneficial effects 
(78% of the HC patients reported reduced severity of continous pain) [143] (Table 4). 
 
5.2. Implantable ONS in TACs other than CH 
Recent multivariate analysis revealed that SUNCT and SUNA, among other refractory chronic 
primary headache patients, showed an high likelihood of response to ONS [50],[145]. 
 
Open-label studies of ONS in TACs other than CH 
A long-term, follow-up (median of 38 months), prospective, open-label ONS study in 9 
medically-intractable headache patients (SUNCT n=6; SUNA n=3) demonstrated beneficial 
effects (4 patients pain-free; 4 patients 81-99% improvement; 1 patient non-responder). The 
AEs were electrode migration and muscle pain over the leads in 1 case per each [144], [146] 
(Table 2A). An open-label, long-term follow-up, prospective series of 16 intractable HC 
patients showed beneficial effects of ONS. Half of the patients (8 out of 16) exhibited high 
(>50%) response rates (yielding a mean 48.9% reduction in monthly headache days) to bilateral 
ONS treatment. It is mentionable that the use of indomethacin dramatically (65.1%) decreased 
in those HC patients who continued to take the drug [147] (Table 2A). Another small-subject-
number (n=7 SUNCT and SUNA patients) study reported ONS to be highly effective and 
demonstrated a favorable safety profile [148]. 
 
5.3. Peripheral nerve blockades (including GON blockade) in TACs other than CH 
Open-label studies of peripheral nerve blockades in HC 
In an open-label case series, indomethacin-unresponsive or -intolerant HC patients (n=22) were 
treated with GON and/or SON or trochlear area blockade with bupivacaine plus mepivacaine. 
They experienced total or partial improvement in pain intensity immediately, which lasted from 
2 to 10 months in all the patients, without any serious AEs [149] (Table 2B).  
5.4. SPG blockade in TACs other than CH 
Case report of SPG blockade in HC 
The case of an 52-year-old female patient with drug-resistant and indomethacin-intolerated HC 
was reported, who was treated with repetitive (twice a week for 6 weeks) SPG blockade with 
bupivacaine (0.6 mL; 0.5%) with a Tx360® device. She experienced beneficial effects both in 
terms of the frequency and intensity of her headache at week 6 post-treatment [150] (Table 5). 
 
6. Conclusion 
Refractory primary headaches, as chronic pain syndromes, have harmful impacts on patients’ 
daily lives. Despite the fact that our incomplete knowledge about the pathogenesis of headache 
disorders expands on a daily basis, there is still no significant progress in marketed drug 
treatments. Peripheral neurostimulation and nerve and ganglion blockades may provide proper 
therapeutic approaches to drug-resistant migraine, CH, and other TACs. No data from meta-
analyses or systematic reviews are available in this field. The levels of evidence and the grades 
of the recommendation have not yet been defined as regards the neuromodulatory techniques 
in primary headaches, and as such, evidence-based therapeutic guidelines are missing in the 
current literature. Therefore, we have categorized the available data based on the different 
designs of the clinical trials they come from, reflecting the level of the existing evidence. 
The concept of our summary statements is based on the quality of clinical evidence and 
level of invasiveness. As summary statements, in drug-refractory EM, either non-invasive 
(i.e., transcutaneous) approaches (including ONS, SONS, and cervical VNS) or the 
mimimally invasive GON blockade with chemical agents can be recommended as first 
choice. No RCTs have been published with invasive methods in EM. In intractable CM, 
as being non-invasive, transcutaneous cervical VNS and GON blockade might be offered 
as first choice, whereas invasive (i.e., implantable) ONS, combined ONS+SONS, and 
transcutaneous auricular VNS techniques can be offered as second choice. In intractable 
ECH, transcutaneous cervical VNS can be offered as first choice, whereas invasive 
electrical stimulation of SPG as second choice. In intractable CCH, transcutaneous 
cervical VNS can be offered as first choice, whereas invasive electrical stimulation of SPG 
and transcutaneous ONS can be offered as second choice. 
 
7. Expert commentary 
The multifactorial nature of primary headache disorders and their, as yet, undetermined 
pathomechanisms lead to therapeutic difficulties. In the case of migraine, the currently available 
preventive drug treatments are inefficient, because only 30-50% of the patients respond well to 
them [151]. Furthermore, the low tolerability ratio and drug-related AEs strongly limit 
recommended acute pharmacotherapies. Management of migraine is incompletely resolved 
[152]. All other forms of primary headaches face the similar difficulties. 
The different neuromodulation methods, including peripheral and central neurostimulation and 
nerve and ganglion blockades, provide us with favorable alternative therapeutic approaches. 
One of the main advantages of these novel techniques is that they can be combined with 
conventional and evidence-based recommended medications. We emphasize that the invasive 
neuromodulatory techniques should be restricted to refractory primary headache patients, 
whereas non-invasive methods can be offered to non-refractory ones as well. Socio-
economically, we should underline their cost-effectiveness. The majority of these techniques 
can be performed in outpatient units. However, we highlight that there are still some areas of 
uncertainty with regards to the optimal way of performing GON blockade for migraine, because 
of the paucity of knowledge about the best local anesthetics to use, as well as about the optimal 
dosage and volume. Based on the data from RCTs in this field, we may recommend 1.5-2.5 mL 
of 0.5% bupivacaine. 
The limitation of these neuromodulatory techniques is that the precise mechanism of their effect, 
(i.e., influencing or inhibiting the activation of the trigeminovascular system) is weakly 
established, both at the preclinical and clinical level. Current evidence for these methods allows 
only a very narrow therapeutic indication (i.e., only medically refractory primary headaches). 
Based on the collected data of their safety issues, it is hard to spread them in a wider indication, 
both in acute and preventative scopes. On the other hand, the BoNTA-hemagglutinin complex 
injection therapy in CM and treatments using fully humanized mAbs targeting the CGRP or the 
CGRP receptor in migraine are already available on the market. These therapies associate with 
very good efficacy and safety features, are easy to use, and they have a chance to move 
implantable devices down the treatment pathway in the near future. 
Until now, based on the literature, predominantly open-label studies have been conducted 
instead of double-blind trials. The number of RCTs is surprisingly low. The difficulties of the 
blind neuromodulation studies are that the patients feel paresthesia during the active phase; 
therefore, patients can easily realize when the stimulator is “ON” versus “OFF” (sham). 
There is a need to develop technically innovative, less invasive, and more user-friendly 
strategies. Real-life studies are warranted in order to get valuable results, not only in strictly 
selected but in the average patient population. The latest meta-analysis of the efficacy and safety 
of BoNTA-hemagglutinin treatment in CM revealed that it reduced the number of migraine 
days per month by 2 days compared with placebo after 24 weeks (-8.4 days in the BoNTA-
hemagglutinin complex group versus -6.6 days in the placebo group). Therefore, future 
therapeutic options can be the combination of BoNTA-hemagglutinin complex with GON 
blockade, ONS, SONS, or transcutaneous VNS. 
The pathomechanism of primary headache disorders is incompletely elucidated; however, some 
evidence points to the role of neuropeptides in the process, particularly CGRP and PACAP. 
Moreover, preclinical and clinical data increasingly associate the tryptophan-kynurenine 
pathway with the genesis of migraine headache. The classical migraine-related neuropeptide is 
CGRP. To date, only the fully humanized mAbs targeting CGRP or its receptors have shown 
up in the therapeutic palette of the prophylactic treatment of EM and CM. A challenging 
question remains the safety of the long-term use of these chemical agents, namely whether they 
have negative impacts on cardiovascular, bowel, endocrine, skin, and bone functions. 
Future perspectives are to achieve personally-tailored medical approaches in this particular 
patient population. The ultimate goal is to find genetic and/or neuroimaging biomarkers among 
primary headache patients in order to obtain correct indications for different neuromodulatory 
techniques, which can serve to maintain an optimal quality of life for headache sufferers. 
 
8. Five-year view 
At present, the main handicap of neuromodulation is the absence of the evidence-based proof 
of efficacy. In the near future, there is the need for well-designed and strictly organized large, 
long-term follow-up, randomized, multicenter, placebo-controlled clinical trials. The results of 
the primary and secondary endpoints should be interpreted with high-level statistical analysis. 
In the far future, the scientific community should press the companies to create and use sham 
stimulation that is not associated with sensory disturbances to achieve clear data. A mobile 
health application system should be built-up, which can provide a bidirectional data exchange 
between headache patients and healthcare professionals. Migraineurs treated with 
neurostimulators should aim to improve their self-management activities. It may also be 
suggested to create a web-based telemonitoring platform in order to allow physicians to 
improve the complex management of their patients.  
The old group of small molecule CGRP receptor antagonists (i.e. gepants) such as olcegepant, 
telcagepant, MK-3207, and BI44370T have already been tested in clinical studies and have 
shown promise in terms of efficacy; however, the liver toxicity associated with long-term use 
restricts their wide-spread clinical application. The latest innovation created three new gepants 
(rimegepant, ubrogepant, and atogepant), which have passed phase III clinical trials and they 
are ahead of final registration. We have a hope that the newly synthesized CGRP receptor 
antagonists will be efficacious and safe as well as [93].  
PACAP has wide biological distribution within the peripheral and central nervous system. It 
might have a fundamental role in the pathomechanism of migraine and CH [153]. Intravenously 
administered PACAP1-38 induced migraine-like attacks in patients with migraine without aura 
[154]. Specific PACAP1-38 plasma level alterations were demonstrated during ictal and 
interictal periods of migraineurs, and also in ECH patients [155], [156]. Based on these 
observations, early phase RCTs are currently running to evaluate the efficacy and safety of 
mAbs targeting PAC1-receptor or PACAP1-38 [157]. Recent preclinical and clinical studies 
have revealed a new possible aspect of migraine management by influencing the kynurenine 
pathway [158-162]. Experimental studies with electrically-activated trigeminovascular system 
pointed to a direct link between PACAP and the kynurenine pathway in rats [163]. In CM 
sufferers, altered serum levels of different kynurenine metabolites have been demonstrated 
[164]. Fully humanized mAbs targeting CGRP or CGRP-receptors and also antibodies against 
PACAP or PAC1-receptors, and possibly even kynurenine pathway-related therapeutic 
approaches may provide us with a novel, innovative opportunity either alone or in combination 
with different neuromodulation techniques in intractable drug-resistant headache patients. 
Key issues 
 
 The currently available acute and preventive medication in primary headache disorders 
do not cover the total patient population due to the variation in efficacy, tolerability, and 
AEs. There is a need for alternative therapeutic options, such as peripheral 
neuromodulation and drugs acting on the peripheral nervous system (e.g., BoNTA-
hemagglutinin complex and CGRP-related mAbs). 
 Invasive neurostimulatory techniques, such as implantable ONS (in CM, CCH, SUNCT, 
SUNA, and HC), implantable SONS+ONS (in CM), implantable cervical VNS (in 
epileptic patients with headache) and implantable SPG stimulation (in ECH and CCH) 
are effective and well-tolerated minimally invasive methods.  
 Non-invasive neurostimulatory tools, such as transcutaneous ONS (in CM and CH), 
transcutaneous SONS (in EM), transcutaneous cervical VNS (in EM, CM, ECH, CCH, 
SUNA, and HC) and transcutaneous auricular VNS (in CM) exhibited beneficial effects, 
and associated with low AE profiles. 
 Nerve and ganglion blockades: GON blockade with chemical agents (e.g., bupivacaine, 
lidocaine, mepivacaine, methylprednisolone, triamcinolone, or betamethasone) is an 
easily applicable, inexpensive method, and is effective and well tolerated in EM, CM, 
CCH, and HC. SPG blockade with chemical agents (e.g., bupivacaine, absolute alcohol, 
or BoNTA-hemagglutinin complex) in CM, ECH, CCH, and HC was effective and 
well tolerated. SPG blockade with RF ablation in ECH and CCH showed beneficial 
effect without serious AEs. 
 BoNTA-hemagglutinin complex injection administered to fixed-sites (i.e., frontal, 
temporal, occipital, or neck muscles), a medication approved by the FDA for the 
prevention of CM, is effective and safe. 
 CGRP-related mAbs, fully humanized antibodies targeting CGRP receptor (erenumab) 
or CGRP itself (eptinezumab, galcanezumab, and fremanezumab), administered 
subcutaneously or intravenously, were effective compared to placebo without any 
serious AEs in EM. Long-term safety data are needed. 
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Tables and figures 
 
Table 1 Peripheral neurostimulation methods in drug-resistant primary headache 
disorders 
 
 
 
 
 
 
Abbreviations: ONS=occipital nerve stimulation; SONS=supraorbital nerve stimulation; 
SPG=sphenopalatine ganglion; SUNA=short-lasting unilateral neuralgiform headache attacks 
with cranial autonomic symptoms; SUNCT=short-lasting unilateral neuralgiform headache 
attacks with conjunctival injection and tearing; VNS=vagal nerve stimulation 
 
INVASIVE NON-INVASIVE 
METHOD INDICATIONS METHOD INDICATIONS 
Implantable ONS Intractable 
chronic migraine 
Intractable 
chronic cluster 
headache 
Intractable 
SUNCT and 
SUNA 
Intractable 
hemicrania 
continua 
Transcutaneous 
ONS 
Drug-refractory 
episodic migraine 
Drug-refractory 
custer headache 
 
Implantable 
SONS+ONS 
Intractable 
chronic migraine 
Transcutaneous 
SONS 
(The Cefaly® 
device) 
Drug-refractory 
episodic migraine  
Implantable 
cervical branch 
VNS 
Epileptic patients 
with headache 
Transcutaneous 
cervical VNS 
(the gammaCore® 
device) 
 
 
 
 
 
 
 
 
______________ 
Transcutaneous 
auricular VNS 
(the NEMOS® 
device) 
Drug-refractory 
episodic and 
chronic migraine 
Drug-refractory 
episodic and 
chronic cluster 
headache 
Drug-refractory 
SUNA 
Drug-refractory 
hemicrania 
continua 
______________ 
Drug-refractory 
chronic migraine 
Implantable SPG 
stimulation 
(The Pulsante 
SPG 
Microstimulator 
System®) 
Intractable 
episodic and 
chronic cluster 
headache 
  
  
Table 2A Data of the occipital nerve neurostimulation (ONS) studies in drug-refractory 
primary headache disorders 
Study design Migraine Cluster headache (CH) Other TACs 
 Episodic 
migraine 
(EM) 
Chronic 
migraine (CM) 
Episodi
c CH 
Chronic CH SUNHA Hemicrani
a continua 
Non-invasive (transcutaneous) occipital nerve stimulation (ONS) 
RCT (for 
prevention) 
(2017) [5] 
n=110 
E=40.91
% (at 100 
Hz) 
versus 
4.55% 
(sham) 
AEs=no 
serious 
AEs 
     
Invasive (implantable) occipital nerve stimulation (ONS) 
RCT (long-
term) (2015) 
[46] 
 n=125 
(intractable 
CM) 
E: headache 
days reduced 
by 7.7 (±8.7) 
days 
AEs: lead 
migration, 
persistent pain 
and/or 
numbness 
    
RCT (2015) 
[47]  
 n=15 
E: 
suprathreshold 
vs.subthreshol
d stimulation  
(1.98+1.56 vs. 
5.65+2.11) 
AEs: none 
    
RCT (2012) 
[48] 
 n=157 
E: failed 
AEs: persistant 
implant side 
pain, lead 
migration 
    
Prospective 
RCT  
(the ICON 
study) (2013) 
[114] 
   ongoing   
Open-label 
prospective 
long-term 
uncontrolled 
 n=37 
E: VAS 
decreased by 
4.9 ± 2.0  
AEs: none 
    
observational 
(2017) [49] 
Open-label 
prospective 
cohort (2018) 
[50] 
 n=35 
E: 28,5% of 
the patients 
AEs: not 
mentioned 
    
Open-label 
prospective 
cohort (2018) 
[50] 
   n=33 
E: 54.5% of 
the patients 
AEs: not 
mentioned 
  
Open-label 
monocentric 
long-term 
(2017) [116] 
   n=35 
E: 66.7% of 
the patients 
AEs: battery 
depletion, 
electrode 
migration 
  
Open-label 
long-term 
prospective 
(2013) [144] 
    n=9 
E: 8 out 
of 9 of 
the 
pateints 
AEs: lead 
migration
, muscle 
pain 
 
Open-label 
long-term 
follow-up 
prospective 
(2017) [147] 
     n=16 
E: 75% of 
the patients 
AEs: none 
Cross-over 
prospective 
randomized 
(2012) [51] 
 n=30 
E: 54-60% of 
patients 
AEs: infection, 
lead migration 
    
Single-center 
combined 
ONS and 
SONS (2013) 
[52] 
 n=14 
E: 71% of 
patients 
AEs: lead 
migration 
    
Long-term 
functional 
outcome 
combined 
ONS and 
SONS (2016) 
[53] 
 n=16 
E: 50% of 
patients 
AEs: lead 
migration, 
supraorbital 
lead allodynia, 
infection 
    
Long-term 
retrospective 
(2013) [54] 
 n=25 
E: 53% of 
patients 
    
AEs: lead 
displacement, 
local infection 
Single-center 
observational 
(2014) [55] 
 n=17 
E: 
NRS=9.8+0.7 
(at baseline), 
5.0+1.6 (at 3 
months); 
5.7+2.6 (at 12 
months) 
AEs: lead 
migration 
    
Single-center 
prospective 
long-term 
(2013) [117] 
   n=24 
E: 89% of the 
patients 
AEs: local 
pain, local 
infections 
  
Single-center 
long-term 
follow-up 
(2017) [118] 
   n=16 
E: 75% of the 
patients 
AEs=electrod
e migration, 
battery 
replacement, 
infection 
 
  
Observationa
l prospective 
(2017) [119] 
   n=67 
E: 59% of the 
patients 
AEs: early 
battery 
depletion 
  
Literature 
review (2017) 
[148] 
    n=7 
E: 100% 
of the 
patient 
AEs: 
none 
 
Abbreviations: AE=adverse event; CH=cluster headache; E=effectiveness (at least 50% improvement 
in headache frequency and/or intensity); GON=greater occipital nerve; n= number of the randomized 
patients; NRS=numeric rating scale; RCT=randomized multicenter double-blind controlled trial; 
SON=supraorbital nerve; SUNHA=short-lasting unilateral neuralgiform headache attacks; 
TAC=trigeminal autonomic cephalalgia; VAS=Visual Analogue Scale 
 
  
Table 2B Data of the greater occipital nerve (GON) blockade studies in intractable 
primary headache disorders 
Study design Migraine Cluster headache (CH) Other TACs 
 Episodic 
migraine 
(EM) 
Chronic 
migraine 
(CM) 
Episodic 
CH 
Chronic CH SUNH
A 
Hemicrani
a continua 
Greater occipital nerve (GON) blockade with chemical agents 
RCT 
(bupivacaine) 
(2017) [58] 
 n=44 
E=frequency
: 21.0 (at 
baseline) 
versus 6.3 (at 
3 month); 
intensity: 8.9 
(at baseline) 
versus 6.3 (at 
3 month) 
AE=local 
pain, vertigo, 
nausea 
    
RCT 
(bupivacaine) 
(2017) [59] 
 
 n=36 
E=number of 
headache 
days: 4.9 
(pretreatment
) to 3.4 (post-
treatment) 
AE=stinging 
sensation, 
presyncope 
    
RCT 
prospective 
pilot 
(bupivacaine) 
(2015) [60] 
 n=23 
E=pain 
intensity: 
VAS: 3.93 
(pre-
injection) 
versus VAS: 
1.55 (post-
injection) 
AE=no 
serious AE 
    
RCT 
(bupivacaine) 
(2015) [61] 
 n=84 
E=headache 
days: from 
18.1 (at 
baseline) to 
8.8 (at 1 
month); 
VAS= from 
8.4 (at 
baseline) to 
5.3 (at 1 
month) 
    
AEs=local 
pain, vertigo 
RCT 
(bupivacaine 
plus 
methylpreniso
lone) (2015) 
[63] 
n=70 
E=30% 
of the 
active 
and 
placebo 
groups 
AEs=pai
n at 
injection 
side 
     
RCT 
(lidocaine plus 
saline versus 
lidocaine plus 
triamcinolone) 
(2014) [64] 
 
n=48 
E= pain 
intensity
: 5.46 
(lidocai
ne plus 
triamcin
olone 
group) 
versus 
5.29 
(lidocai
ne plus 
saline 
group) 
at week 
8; 
headach
e 
frequenc
y: 8.38 
versus 
9.42 at 
week 8 
AEs=no 
serious 
AEs 
     
RCT 
prospective 
(bupivacaine) 
(2018) [65] 
 
n=60 
E=pain 
scale 
score 
from 9 
to 1 (in 
GON 
block 
group) 
AEs=no 
serious 
AEs 
     
RCT (pulsed 
RF versus 
depomethylpr
n=9 n=20 
E=headache 
frequency 
    
ednisolone) 
(2015) [165] 
from 3.140 
(at baseline) 
to 1.810 (at 6 
week) in 
steroid 
injection 
group; 
from 3.640 
(at baseline) 
to 1.708 (at 6 
week) in 
pulsed RF 
group 
AE=no 
serious AEs 
RCT (long- 
and rapid 
acting salts of 
betamethason
e) (2005) 
[128] 
  n=16 
E=85% 
of the 
patients 
AEs= 
transient 
pain at 
the 
injection 
site 
n=7 
E=85% of the 
patients 
AEs= transient 
pain at the 
injection site 
  
Open-label 
(bupivacaine) 
(2016) [66] 
n=78 
E=attac
k 
frequenc
y: from 
15.73 
(at 
baseline
) to 4.52 
(at 
month 
3) in 
group 
GON 
blockad
e versus 
from 
13.76 to 
3.28 in 
group 
GON 
blockad
e + 
prophyl
actic 
medicati
on; 
headach
e 
severity: 
     
from 
8.26 to 
5.16 (in 
group 
GON 
blockad
e) 
versus 
from 
8.80 to 
5.96 (in 
group 
GON 
blockad
e + 
prophyl
actic 
medicati
on) 
AEs=no 
serious 
AEs 
Open-label 
(bupivacaine) 
(2017) [59] 
n=18 
patients 
(22 aura 
sympto
ms) 
E=86% 
of the 
aura 
sympto
ms 
AEs=no 
serious 
AEs 
     
Open-label 
retrospective 
(bupivacaine) 
(2017) [67] 
 n=41 
E=headache 
frequency: 
unilateral 
GON block: 
from 20.0 (at 
baseline) to 
9.9 (at 3 
month post-
treatment) 
versus 
bilateral 
GON block: 
from 20.44 
to 12.00; 
pain 
intensity: 
unilateral 
GON block: 
from 7.05 to 
    
5.11 versus 
bilateral 
GON block: 
from 6.84 to 
5.91 
AEs= no 
serious AEs 
Open-label 
observational 
case series 
(high volume 
lidocaine+tria
mcinolone) 
(2018) [129] 
   n=10 
E=100% of the 
patients (for mean of 
65.1 days post-
treatment pain-free 
period) 
AEs=no serious AEs 
  
Open-label 
prospective 
(methylpredni
solone) (2014) 
[130] 
   n=83 
E=57% of the 
patients 
AEs=tenderness at 
the injection site, 
neck stiffness, 
dizziness 
  
Open-label 
case series 
(GON and/or 
SON or 
trochlear area) 
(bupivacaine 
plus 
mepivacaine) 
(2012) [149] 
     n=22 
E=100% of 
the patients 
(reduction 
in pain 
intensity) 
AEs=no 
serious 
AEs 
Retrospective 
cohort study 
(bupivacaine, 
lidocaine) 
(2018) [68] 
n=562 
E=58% 
of the 
patients 
AEs=va
sovagal 
sympto
ms, 
burning 
feeling 
at the 
injection 
site 
     
Retrospective 
analysis 
(betamethason
e) (2012) 
[132] 
  n=31 n=29 
E=64.8% of the 
patients (after first 
injection) 
AEs=local pain, 
facial oedema, 
insomnia, acne, 
bradycardia, 
syncope 
  
Prospective 
observational 
  n=61 n=40 
E=83.2% of the 
patients 
  
(triamcinolone 
plus 
bupivacaine) 
(2017) [133] 
AEs=no serious AEs 
Single-center 
retrospective 
comparative 
(GON 
blockade with 
methylprednis
olone versus 
oral steroid 
with 
prednisone 
and 
dexamethason
e) (2018) 
[131] 
  n=29 n=12 
E=82.7% of oral 
steroid encounters 
(n=81) and 64.4% of 
GON injection 
encounters (n=59) 
AEs=no AEs were 
recorded 
  
Abbreviations: AE=adverse event; CH=cluster headache; E=effectiveness (at least 50% improvement 
in headache frequency and/or intensity); GON=greater occipital nerve; n= number of the randomized 
patients; NRS=numeric rating scale; RCT=randomized multicenter double-blind controlled trial; 
SON=supraorbital nerve; SUNHA=short-lasting unilateral neuralgiform headache attacks; 
TAC=trigeminal autonomic cephalalgia; VAS=Visual Analogue Scale 
 
Table 3. Data of the non-invasive (transcutaneous) and invasive (implantable) 
supraorbital nerve stimulation (SONS) studies in intractable primary headache 
disorders 
 
Study design Migraine Cluster headache 
(CH) 
Other TACs 
 Episodic 
migraine 
(EM) 
Chronic 
migraine 
(CM) 
Episodic 
CH 
Chronic 
CH 
SUNHA Hemicrania 
continua 
RCT of 
transcutaneous 
SONS (the 
Cefaly® device) 
(The PREMICE 
study) (2013) 
[11] 
n=67 
E=38.1% of 
the patients 
AEs=none 
     
RCT of 
transcutaneous 
SONS (the 
Cefaly® device) 
(2013) [12] 
n=2313 
E=54.4% of 
the patients 
AEs=local 
paresthesia 
     
RCT of 
transcutaneous 
SONS (the 
Cefaly® device) 
(2018) [13] 
n=109 
E=59% of 
the patients 
AEs=no 
serious AEs 
     
Single-center 
combined 
implantable ONS 
and implantable 
SONS (2013) 
[52] 
 n=14 
E=71% of 
patients 
AEs=lead 
migration 
    
Long-term 
functional 
outcome 
combined 
implantable ONS 
and implantable 
SONS (2016) 
[53] 
 n=16 
E=50% of 
the patients 
AEs=lead 
migration, 
supraorbital 
lead 
allodynia, 
infection 
    
Abbreviations: AE=adverse event; E=effectiveness (at least 50% improvement in headache frequency 
and/or intensity); n= number of the randomized patients; ONS=occipital nerve stimulation; 
RCT=randomized multicenter double-blind controlled trial; SUNHA=short-lasting unilateral 
neuralgiform headache attacks; TAC=trigeminal autonomic cephalalgia; VAS=Visual Analogue Scale 
 
Table 4. Data of the non-invasive vagus nerve stimulation (VNS) studies in drug-
refractory primary headache disorders 
 
Study design Migraine Cluster headache (CH) Other TACs 
 Episodic 
migraine 
(EM) 
Chronic 
migraine 
(CM) 
Episodic 
CH 
Chronic CH SUNH
A 
Hemicrania 
continua 
the gammaCore® device (cervical branch of the vagus nerve) 
RCT (for acute 
and preventive 
treatment) 
(the PREVA 
study) (2016) [17] 
 
   n=97 
E=40% of 
the patients 
AEs=headac
he, 
nasopharyng
itis, 
dizziness, 
oropharynge
al pain, neck 
pain 
 
  
RCT (for acute 
treatment) 
(the ACT1 study) 
(2016) [107] 
  n=38 
E=34.2% 
of the 
patients 
AEs=burni
ng, 
tingling, 
soreness, 
stinging, 
lip or facial 
drooping 
n=22 
E=failed 
AEs=burnin
g, tingling, 
soreness, 
stinging, lip 
or facial 
drooping 
  
RCT (for acute 
treatment) 
(the ACT2 study) 
(2018) [108] 
  n=27 
E=48% 
AEs=not 
relevant 
n=65 
E=5% 
AEs=not 
relevant 
  
RCT prospective 
pilot (for 
prevention) (the 
EVENT study) 
(2016) [29] 
 n=59 
E= 9.1% (at 
2 month) 
E=46.7% (at 
8 month) 
AEs=eye 
twitch, 
facial 
pain/numbn
ess, 
gastrointesti
nal 
symptoms, 
upper 
respiratory 
tract 
infection 
  
 
  
RCT (for acute 
treatment) (the 
n=248      
PRESTO study) 
(2018) [30] 
E=at 30 
min: 
12.7% 
versus 
4.2%; at 
60 min: 
21.0% 
versus 
10.0%; 
at 120 
min: 
30.4% 
versus 
19.7% 
AEs=no 
serious 
AEs 
Open-label 
single-arm 
multicenter (for 
acute treatment) 
(2015) [18] 
 n=36 (high-
frequency 
EM n=14) 
E=51% (at 2 
h after 
treatment) 
AEs=stingli
ng and 
pricking 
sensation 
 
 
    
Open-label single-
arm multiple-
attack pilot (for 
acute treatment) 
(2014) [31] 
n=30 
E=22% 
(pain-free 
rate) 
AEs=nec
k 
twitching
, raspy 
voice, 
redness at 
the 
device 
site 
     
Open-label 
preliminary 
single-arm safety 
(for acute 
treatment) (2017) 
[32] 
n=9 
E=46.8% 
of the 
treated 
migraine 
attacks 
AEs=non
e 
 
     
Open.label 
menstrual/menstru
ally-related mini-
n=56 
E: 39% 
of 
patients 
     
prophylaxis 
(2016) [33] 
AEs: no 
serious 
AEs 
Open-label real-
world prospective 
clinical audit 
(2018) [142] 
 
 n=23 
E: 2 out of 
23 patients 
(at least 
30% 
reduction in 
headache 
days/episod
es) 
AEs=no 
serious AEs 
 n=12 
E: 1 out of 
12 patients 
(at least 30% 
reduction in 
headache 
days/episode
s) 
AEs=no 
serious AEs 
 n=2 
E: 
none 
of the 
patient
s 
AEs=n
o 
seriou
s AEs 
 
n=4 
E: 2 out of 
4 patients 
(at least 
30% 
reduction in 
headache 
days/episod
es) 
AEs=no 
serious AEs 
Single-center 
prospective 
observational 
cohort (for acute 
and preventive 
treatment) (2015) 
[34] 
n=10 
E=VAS=
8 (at 
baseline) 
versus 
VAS=3.5 
(at 3 
month 
post-
treatment
) 
E=headac
he days: 
11.3 (at 
baseline) 
versus 
5.7 (at 3 
month 
post-
treatment
) 
AEs=no 
serious 
AEs 
n=10 
E=VAS=8 
(at baseline) 
versus 
VAS=5 (at 
3 month 
post-
treatment) 
E=headache 
days: 18.1 
(at baseline) 
versus 8.1 
(at 3 month 
post-
treatment) 
AEs=no 
serious AEs 
    
Single-center 
(2017) [143] 
     n=9 
E=78% of 
the patients 
AEs=no 
serious 
the NEMOS® device (auricular branch of the vagus nerve) 
Single-center 
sandomized 
parallel-group 
double-blind (for 
prevention) (2015) 
[36] 
 n=46 
E=29.4% of 
the patients 
(at 1 Hz); 
13.3% of 
the patients 
(at 25 Hz) 
AEs=pain, 
paresthesia, 
pruritus, 
    
erythema, 
ulcer or scab 
Abbreviations: AE=adverse event; CH=cluster headache; E=effectiveness (at least 50% improvement 
in headache frequency and/or intensity); n=number of the randomized patients; RCT=randomized 
multicenter double-blind controlled trial; SUNHA=short-lasting unilateral neuralgiform headache 
attacks; TAC=trigeminal autonomic cephalalgia; VAS=Visual Analogue Scale 
Table 5. Data of the sphenopalatine ganglion (SPG) stimulation and blockade studies in 
drug-refractory primary headache disorders 
 
Study design Migraine Cluster headache (CH) Other TACs 
 Episodic 
migraine 
(EM) 
Chronic 
migraine (CM) 
Episodi
c CH 
Chronic CH SUNH
A 
Hemicrani
a continua 
Electrical stimulation of SPG 
Multicenter RCT 
(the PATHWAY CH-
I study) (2013) [125] 
   n=32 
E=68% of the 
patients 
AEs=loss of 
sensation in 
the maxillary 
nerve region 
  
Long-term open-
label follow-up of 
the PATHWAY CH-I 
study (attack 
remission) (2016) 
[122] 
   n=33 
E=30% of the 
patients at 
least one 
episode of 
complete 
attack 
remission 
AEs=no 
serious AEs 
  
Long-term open-label 
follow-up of the 
PATHWAY CH-I 
study (effectiveness) 
(2017) [126] 
 
   n=33 
E=61% of the 
patients 
AEs=no 
serious AEs 
  
The PATHWAY R-1 
register study (2018) 
[127] 
  n=7 
E=71.4
% 
(frequen
cy) 
AEs= 
not 
detailed 
n=78 
E=65% 
AEs=73% 
postoperative 
sequelae 
  
Radiofrequency (RF) ablation of SPG 
Prospective open-
label follow-up 
(pulsed RF) (2016) 
[136] 
  n=13 
E=85% 
AEs=no 
serious
AEs 
n=3 
E=33% 
AEs=no 
serious AEs 
  
Case series (2015) 
[137] 
 
   n=3 
E=2 out of 3 
patients no 
pain relief 
after pulsed 
RF; 3 out of 3 
patients pain-
free after 
continuous 
  
RF + SPG 
blockade 
Ganglion (SPG) blockade with chemical agents 
RCT pilot 
(bupivacaine) (2015) 
[73] 
 n=41 
E=4.20 versus 
2.85 NRS 
score 
AE=lacrimatio
n, nasal 
irritation, 
mouth 
numbness, bad 
taste 
    
Long-term RCT pilot 
(bupivacaine) (2015) 
[74] 
 n=41 
E=17.44 versus 
22.82 headache 
days at 1 
month post-
treatment 
AE=lacrimatio
n, taste 
disturbances, 
oral numbing 
    
Prospective open-
label uncontrolled 
(onabotulinumtoxinA) 
(2017) [138] 
 n=10 
E=80% 
AE=local 
discomfort in 
the face and 
jaw 
    
Retrospective open-
label uncontrolled 
(lidocaine) (2018) 
[76]  
 n=55 
E=78.2% of 
the patients 
AEs=no 
serious AEs 
    
Prospective open-label 
uncontrolled 
(onabotulinumtoxinA) 
(2016) [138] 
   n=10 
E=50% 
AE=epistaxis, 
accomodation 
problem 
  
Retrospective single-
center open-label 
(absolute alcohol) 
(2014) [139] 
  n=14 
E=76.5
% 
AE= no 
serious 
AE 
   
Case report 
(bupivacaine) (2016) 
[150] 
     n=1 
E= 
frequency: 
from 7/7 
(baseline) 
to 2/7 (at 
week 4) 
and 0/7 (at 
week 6); 
intensity: 
VAS=6/10 
(at 
baseline) to 
1/10 (at 
week 4) 
and 0/10 
(at week 6) 
AE=no 
serious AE 
Abbreviations: AE=adverse event; E=effectiveness (at least 50% improvement in headache frequency 
and/or intensity); n=number of the randomized patients; NRS=numeric rating scale, RCT=randomized 
multicenter double-blind controlled trial; RF=radio frequency; SPG=sphenopalatine ganglion; 
SUNHA=short-lasting unilateral neuralgiform headache attacks; TAC=trigeminal autonomic 
cephalalgia; VAS=Visual Analogue Scale 
 
References 
Papers of special note have been highlighted as either of interest (*) or of considerable interest 
(**) to readers. 
 
1. Schwedt TJ, Vargas B. Neurostimulation for Treatment of Migraine and Cluster 
Headache. Pain Medicine, 16(9), 1827-1834 (2015). 
2. Schuster NM, Rapoport AM. New strategies for the treatment and prevention of 
primary headache disorders. Nature Reviews. Neurology, 12(11), 635-650 (2016). 
** An important summary of the updated management of primary headache disorders. 
3. Zagami AS. Treatment of the Patient with Refractory Headache. Current Pain and 
Headache Reports, 22(4), 23 (2018). 
** A paper summarizing all the important aspects of the treatment of refractory 
primary headaches. 
4. Robbins MS, Lipton RB. Transcutaneous and Percutaneous Neurostimulation for 
Headache Disorders. Headache, 57 Suppl 1, 4-13 (2017). 
** It is a well-structured review with high scientific impact concerning non-invasive 
neurostimulation in headache disorders. 
5. Liu Y, Dong Z, Wang R et al. Migraine Prevention Using Different Frequencies of 
Transcutaneous Occipital Nerve Stimulation: A Randomized Controlled Trial. The 
Journal of Pain 18(8), 1006-1015 (2017). 
6. Nguyen JP, Nizard J, Kuhn E et al. A good preoperative response to transcutaneous 
electrical nerve stimulation predicts a better therapeutic effect of implanted occipital 
nerve stimulation in pharmacologically intractable headaches. Neurophysiologie 
Clinique, 46(1), 69-75 (2016). 
7. Solomon S, Guglielmo KM. Treatment of headache by transcutaneous electrical 
stimulation. Headache, 25(1), 12-15 (1985). 
8. Russo A, Tessitore A, Esposito F et al. Functional Changes of the Perigenual Part of 
the Anterior Cingulate Cortex after External Trigeminal Neurostimulation in Migraine 
Patients. Frontiers in Neurology, 8, 282 (2017). 
9. Magis D, D'Ostilio K, Thibaut A et al. Cerebral metabolism before and after external 
trigeminal nerve stimulation in episodic migraine. Cephalalgia, 37(9), 881-891 
(2017). 
10. Schoenen J, Coppola G. Efficacy and mode of action of external trigeminal 
neurostimulation in migraine. Expert Review of Neurotherapeutics, 18(7), 545-555 
(2018). 
** This is an excellent overview of the efficacy and safety of the Cefaly® device in 
migraine. 
11. Schoenen J, Vandersmissen B, Jeangette S et al. Migraine prevention with a 
supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology, 
80(8), 697-704 (2013). 
12. Magis D, Sava S, d'Elia TS, Baschi R, Schoenen J. Safety and patients' satisfaction of 
transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly(R) device in 
headache treatment: a survey of 2,313 headache sufferers in the general population. 
The Journal of Headache and Pain, 14, 95 (2013). 
13. Chou DE, Shnayderman Yugrakh M, Winegarner D, Rowe V, Kuruvilla D, Schoenen 
J. Acute migraine therapy with external trigeminal neurostimulation (ACME): A 
randomized controlled trial. Cephalalgia,  333102418811573 (2018). 
14. Penning S, Schoenen J. A survey on migraine attack treatment with the CEFALY((R)) 
device in regular users. Acta neurologica Belgica, 117(2), 547-549 (2017). 
15. Beekwilder JP, Beems T. Overview of the clinical applications of vagus nerve 
stimulation. Journal of Clinical Neurophysiology, 27(2), 130-138 (2010). 
16. Lyubashina OA, Sokolov AY, Panteleev SS. Vagal afferent modulation of spinal 
trigeminal neuronal responses to dural electrical stimulation in rats. Neuroscience, 
222, 29-37 (2012). 
17. Gaul C, Diener HC, Silver N et al. Non-invasive vagus nerve stimulation for 
PREVention and Acute treatment of chronic cluster headache (PREVA): A 
randomised controlled study. Cephalalgia 36(6), 534-546 (2016). 
18. Barbanti P, Grazzi L, Egeo G, Padovan AM, Liebler E, Bussone G. Non-invasive 
vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: 
an open-label study. The Journal of Headache and Pain, 16, 61 (2015). 
19. Johnson RL, Wilson CG. A review of vagus nerve stimulation as a therapeutic 
intervention. Journal of Inflammation Research, 11, 203-213 (2018). 
20. Leone M, Cecchini AP. Central and Peripheral Neural Targets for Neurostimulation of 
Chronic Headaches. Current Pain and Headache Reports, 21(3), 16 (2017). 
21. Csati A, Tajti J, Tuka B, Edvinsson L, Warfvinge K. Calcitonin gene-related peptide 
and its receptor components in the human sphenopalatine ganglion -- interaction with 
the sensory system. Brain Research, 1435, 29-39 (2012). 
22. Csati A, Tajti J, Kuris A, Tuka B, Edvinsson L, Warfvinge K. Distribution of 
vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric 
oxide synthase, and their receptors in human and rat sphenopalatine ganglion. 
Neuroscience, 202, 158-168 (2012). 
23. Chen SP, Ay I, de Morais AL et al. Vagus nerve stimulation inhibits cortical spreading 
depression. Pain, 157(4), 797-805 (2016). 
24. Ferguson AV, Samson WK. The orexin/hypocretin system: a critical regulator of 
neuroendocrine and autonomic function. Frontiers in Neuroendocrinology, 24(3), 141-
150 (2003). 
25. Holland P, Goadsby PJ. The hypothalamic orexinergic system: pain and primary 
headaches. Headache, 47(6), 951-962 (2007). 
26. Strother LC, Srikiatkhachorn A, Supronsinchai W. Targeted Orexin and Hypothalamic 
Neuropeptides for Migraine. Neurotherapeutics 15(2), 377-390 (2018). 
27. Sadler RM, Purdy RA, Rahey S. Vagal nerve stimulation aborts migraine in patient 
with intractable epilepsy. Cephalalgia, 22(6), 482-484 (2002). 
28. Yuan H, Silberstein SD. Vagus Nerve and Vagus Nerve Stimulation, a Comprehensive 
Review: Part I. Headache, 56(1), 71-78 (2016). 
29. Silberstein SD, Calhoun AH, Lipton RB et al. Chronic migraine headache prevention 
with noninvasive vagus nerve stimulation: The EVENT study. Neurology, 87(5), 529-
538 (2016). 
30. Tassorelli C, Grazzi L, de Tommaso M et al. Noninvasive vagus nerve stimulation as 
acute therapy for migraine: The randomized PRESTO study. Neurology, 91(4), e364-
e373 (2018). 
31. Goadsby PJ, Grosberg BM, Mauskop A, Cady R, Simmons KA. Effect of noninvasive 
vagus nerve stimulation on acute migraine: an open-label pilot study. Cephalalgia, 
34(12), 986-993 (2014). 
32. Grazzi L, Egeo G, Liebler E, Padovan AM, Barbanti P. Non-invasive vagus nerve 
stimulation (nVNS) as symptomatic treatment of migraine in young patients: a 
preliminary safety study. Neurological Sciences, 38(Suppl 1), 197-199 (2017). 
33. Grazzi L, Egeo G, Calhoun AH, McClure CK, Liebler E, Barbanti P. Non-invasive 
Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually 
related migraine: an open-label study. The Journal of Headache and Pain, 17(1), 91 
(2016). 
34. Kinfe TM, Pintea B, Muhammad S et al. Cervical non-invasive vagus nerve 
stimulation (nVNS) for preventive and acute treatment of episodic and chronic 
migraine and migraine-associated sleep disturbance: a prospective observational 
cohort study. The Journal of Headache and Pain, 16, 101 (2015). 
35. Redgrave J, Day D, Leung H et al. Safety and tolerability of Transcutaneous Vagus 
Nerve stimulation in humans; a systematic review. Brain Stimulation, 11(6), 1225-
1238 (2018). 
* This paper describes the safety issues of the non-invasive vagal nerve stimulation in 
headaches. 
36. Straube A, Ellrich J, Eren O, Blum B, Ruscheweyh R. Treatment of chronic migraine 
with transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-
VNS): a randomized, monocentric clinical trial. The Journal of Headache and Pain, 
16, 543 (2015). 
37. Mercante B, Ginatempo F, Manca A, Melis F, Enrico P, Deriu F. Anatomo-
Physiologic Basis for Auricular Stimulation. Medical Acupuncture, 30(3), 141-150 
(2018). 
38. Trentman TL, Schwedt TJ. Occipital nerve stimulation and beyond: when is invasive 
peripheral stimulation for headaches appropriate? Expert Review of 
Neurotherapeutics, 16(3), 237-239 (2016). 
39. Martelletti P, Jensen RH, Antal A et al. Neuromodulation of chronic headaches: 
position statement from the European Headache Federation. The Journal of Headache 
and Pain, 14, 86 (2013). 
** This article contains the crucial position statement of the European Headache 
Federation about neuromodulatory techniques in drug-refractory headaches. 
40. Magis D, Schoenen J. Advances and challenges in neurostimulation for headaches. 
The Lancet. Neurology, 11(8), 708-719 (2012). 
41. Bartsch T, Goadsby PJ. Stimulation of the greater occipital nerve induces increased 
central excitability of dural afferent input. Brain, 125(Pt 7), 1496-1509 (2002). 
42. Bartsch T, Goadsby PJ. Increased responses in trigeminocervical nociceptive neurons 
to cervical input after stimulation of the dura mater. Brain, 126(Pt 8), 1801-1813 
(2003). 
43. Ambrosini A, Schoenen J. Invasive pericranial nerve interventions. Cephalalgia, 
36(12), 1156-1169 (2016). 
44. May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. 
Nature reviews. Neurology, 12(8), 455-464 (2016). 
45. Headache Classification Committee of the International Headache Society (IHS) The 
International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38(1), 1-
211 (2018). 
46. Dodick DW, Silberstein SD, Reed KL et al. Safety and efficacy of peripheral nerve 
stimulation of the occipital nerves for the management of chronic migraine: long-term 
results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia, 
35(4), 344-358 (2015). 
47. Slotty PJ, Bara G, Kowatz L et al. Occipital nerve stimulation for chronic migraine: a 
randomized trial on subthreshold stimulation. Cephalalgia, 35(1), 73-78 (2015). 
48. Silberstein SD, Dodick DW, Saper J et al. Safety and efficacy of peripheral nerve 
stimulation of the occipital nerves for the management of chronic migraine: results 
from a randomized, multicenter, double-blinded, controlled study. Cephalalgia, 
32(16), 1165-1179 (2012). 
49. Rodrigo D, Acin P, Bermejo P. Occipital Nerve Stimulation for Refractory Chronic 
Migraine: Results of a Long-Term Prospective Study. Pain Physician, 20(1), E151-
E159 (2017). 
50. Miller S, Watkins L, Matharu M. Long-term follow up of intractable chronic short 
lasting unilateral neuralgiform headache disorders treated with occipital nerve 
stimulation. Cephalalgia, 38(5), 933-942 (2018). 
51. Serra G, Marchioretto F. Occipital nerve stimulation for chronic migraine: a 
randomized trial. Pain Physician, 15(3), 245-253 (2012). 
52. Hann S, Sharan A. Dual occipital and supraorbital nerve stimulation for chronic 
migraine: a single-center experience, review of literature, and surgical considerations. 
Neurosurgical Focus, 35(3), E9 (2013). 
53. Clark SW, Wu C, Boorman DW et al. Long-Term Pain Reduction Does Not Imply 
Improved Functional Outcome in Patients Treated With Combined Supraorbital and 
Occipital Nerve Stimulation for Chronic Migraine. Neuromodulation, 19(5), 507-514 
(2016). 
54. Palmisani S, Al-Kaisy A, Arcioni R et al. A six year retrospective review of occipital 
nerve stimulation practice--controversies and challenges of an emerging technique for 
treating refractory headache syndromes. The Journal of Headache and Pain, 14, 67 
(2013). 
55. Notaro P, Buratti E, Meroni A, Montagna MC, Rubino FG, Voltolini A. The effects of 
peripheral occipital nerve stimulation for the treatment of patients suffering from 
chronic migraine: a single center experience. Pain Physician, 17(3), E369-374 (2014). 
56. Lendvai IS, Maier A, Scheele D, Hurlemann R, Kinfe TM. Spotlight on cervical vagus 
nerve stimulation for the treatment of primary headache disorders: a review. Journal 
of Pain Research, 11, 1613-1625 (2018). 
57. Pintea B, Hampel K, Bostrom J et al. Extended Long-Term Effects of Cervical Vagal 
Nerve Stimulation on Headache Intensity/Frequency and Affective/Cognitive 
Headache Perception in Drug Resistant Complex-Partial Seizure Patients. 
Neuromodulation, 20(4), 375-382 (2017). 
58. Gul HL, Ozon AO, Karadas O, Koc G, Inan LE. The efficacy of greater occipital 
nerve blockade in chronic migraine: A placebo-controlled study. Acta Neurologica 
Scandinavica, 136(2), 138-144 (2017). 
59. Cuadrado ML, Aledo-Serrano A, Navarro P et al. Short-term effects of greater 
occipital nerve blocks in chronic migraine: A double-blind, randomised, placebo-
controlled clinical trial. Cephalalgia, 37(9), 864-872 (2017). 
60. Palamar D, Uluduz D, Saip S, Erden G, Unalan H, Akarirmak U. Ultrasound-guided 
greater occipital nerve block: an efficient technique in chronic refractory migraine 
without aura? Pain Physician, 18(2), 153-162 (2015). 
61. Inan LE, Inan N, Karadas O et al. Greater occipital nerve blockade for the treatment of 
chronic migraine: a randomized, multicenter, double-blind, and placebo-controlled 
study. Acta Neurologica Scandinavica, 132(4), 270-277 (2015). 
62. Cuadrado ML, Aledo-Serrano A, Lopez-Ruiz P et al. Greater occipital nerve block for 
the acute treatment of prolonged or persistent migraine aura. Cephalalgia, 37(8), 812-
818 (2017). 
63. Dilli E, Halker R, Vargas B et al. Occipital nerve block for the short-term preventive 
treatment of migraine: A randomized, double-blinded, placebo-controlled study. 
Cephalalgia, 35(11), 959-968 (2015). 
64. Kashipazha D, Nakhostin-Mortazavi A, Mohammadianinejad SE, Bahadoram M, 
Zandifar S, Tarahomi S. Preventive effect of greater occipital nerve block on severity 
and frequency of migraine headache. Global Journal of Health Science, 6(6), 209-213 
(2014). 
65. Korucu O, Dagar S, Corbacioglu SK, Emektar E, Cevik Y. The effectiveness of 
greater occipital nerve blockade in treating acute migraine-related headaches in 
emergency departments. Acta Neurologica Scandinavica, 138(3), 212-218 (2018). 
66. Inan N, Inan LE, Coskun O, Tunc T, Ilhan M. Effectiveness of Greater Occipital 
Nerve Blocks in Migraine Prophylaxis. Noro Psikiyatri Arsivi, 53(1), 45-48 (2016). 
67. Unal-Artik HA, Inan LE, Atac-Ucar C, Yoldas TK. Do bilateral and unilateral greater 
occipital nerve block effectiveness differ in chronic migraine patients? Neurological 
Sciences, 38(6), 949-954 (2017). 
68. Allen SM, Mookadam F, Cha SS, Freeman JA, Starling AJ, Mookadam M. Greater 
Occipital Nerve Block for Acute Treatment of Migraine Headache: A Large 
Retrospective Cohort Study. Journal of The American Board of Family Medicine , 
31(2), 211-218 (2018). 
69. Zhang H, Yang X, Lin Y, Chen L, Ye H. The efficacy of greater occipital nerve block 
for the treatment of migraine: A systematic review and meta-analysis. Clinical 
Neurology and Neurosurgery, 165, 129-133 (2018). 
* The authors give the basic principle of the greater occipital nerve block for the 
treatment of migraine. 
70. Tang Y, Kang J, Zhang Y, Zhang X. Influence of greater occipital nerve block on pain 
severity in migraine patients: A systematic review and meta-analysis. The American 
Journal of Emergency Medicine, 35(11), 1750-1754 (2017). 
71. Vukovic Cvetkovic V, Jensen RH. Neurostimulation for the treatment of chronic 
migraine and cluster headache. Acta Neurologica Scandinavica,  (2018). 
72. Khan S, Schoenen J, Ashina M. Sphenopalatine ganglion neuromodulation in 
migraine: what is the rationale? Cephalalgia, 34(5), 382-391 (2014). 
73. Cady R, Saper J, Dexter K, Manley HR. A double-blind, placebo-controlled study of 
repetitive transnasal sphenopalatine ganglion blockade with tx360((R)) as acute 
treatment for chronic migraine. Headache, 55(1), 101-116 (2015). 
74. Cady RK, Saper J, Dexter K, Cady RJ, Manley HR. Long-term efficacy of a double-
blind, placebo-controlled, randomized study for repetitive sphenopalatine blockade 
with bupivacaine vs. saline with the Tx360 device for treatment of chronic migraine. 
Headache, 55(4), 529-542 (2015). 
75. Bratbak DF, Nordgard S, Stovner LJ et al. Pilot study of sphenopalatine injection of 
onabotulinumtoxinA for the treatment of intractable chronic migraine. Cephalalgia, 
37(4), 356-364 (2017). 
76. Binfalah M, Alghawi E, Shosha E, Alhilly A, Bakhiet M. Sphenopalatine Ganglion 
Block for the Treatment of Acute Migraine Headache. Pain Research and Treatment, 
2018, 2516953 (2018). 
77. Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxins: structure, 
function and therapeutic utility. Trends in Biochemical Sciences, 27(11), 552-558 
(2002). 
78. Frampton JE. OnabotulinumtoxinA (BOTOX(R)): a review of its use in the 
prophylaxis of headaches in adults with chronic migraine. Drugs, 72(6), 825-845 
(2012). 
79. De Boulle K, Fagien S, Sommer B, Glogau R. Treating glabellar lines with botulinum 
toxin type A-hemagglutinin complex: a review of the science, the clinical data, and 
patient satisfaction. Clinical Interventions in Aging, 5, 101-118 (2010). 
80. Cernuda-Morollon E, Ramon C, Martinez-Camblor P, Serrano-Pertierra E, Larrosa D, 
Pascual J. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients 
with chronic migraine. Pain, 156(5), 820-824 (2015). 
81. Cady R, Turner I, Dexter K, Beach ME, Cady R, Durham P. An exploratory study of 
salivary calcitonin gene-related peptide levels relative to acute interventions and 
preventative treatment with onabotulinumtoxinA in chronic migraine. Headache, 
54(2), 269-277 (2014). 
82. Hollanda L, Monteiro L, Melo A. Botulinum toxin type a for cephalic cutaneous 
allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial. 
Neurology International, 6(4), 5133 (2014). 
83. Aurora SK, Dodick DW, Turkel CC et al. OnabotulinumtoxinA for treatment of 
chronic migraine: results from the double-blind, randomized, placebo-controlled phase 
of the PREEMPT 1 trial. Cephalalgia, 30(7), 793-803 (2010). 
84. Diener HC, Dodick DW, Aurora SK et al. OnabotulinumtoxinA for treatment of 
chronic migraine: results from the double-blind, randomized, placebo-controlled phase 
of the PREEMPT 2 trial. Cephalalgia, 30(7), 804-814 (2010). 
85. Szok D, Csati A, Vecsei L, Tajti J. Treatment of Chronic Migraine with 
OnabotulinumtoxinA: Mode of Action, Efficacy and Safety. Toxins, 7(7), 2659-2673 
(2015). 
86. Tajti J, Szok D, Tuka B et al. [Botulinum neurotoxin--a therapy in migraine]. 
Ideggyogyaszati Szemle, 65(3-4), 77-82 (2012). 
87. Vecsei L, Majlath Z, Szok D, Csati A, Tajti J. Drug safety and tolerability in 
prophylactic migraine treatment. Expert opinion on drug safety, 14(5), 667-681 
(2015). 
88. Herd CP, Tomlinson CL, Rick C et al. Botulinum toxins for the prevention of 
migraine in adults. The Cochrane Database of Systematic Reviews, 6, CD011616 
(2018). 
89. Tassorelli C, Tedeschi G, Sarchielli P et al. Optimizing the long-term management of 
chronic migraine with onabotulinumtoxinA in real life. Expert Review of 
Neurotherapeutics, 18(2), 167-176 (2018). 
90. Negro A, Curto M, Lionetto L, Giamberardino MA, Martelletti P. Chronic migraine 
treatment: from OnabotulinumtoxinA onwards. Expert Review of Neurotherapeutics, 
16(10), 1217-1227 (2016). 
91. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral 
circulation of humans during migraine headache. Annals of Neurology, 28(2), 183-187 
(1990). 
92. Edvinsson L. The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in 
Migraine. Headache, 57 Suppl 2, 47-55 (2017). 
93. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new 
migraine therapies - successful translation from bench to clinic. Nature Reviews. 
Neurology, 14(6), 338-350 (2018). 
*An outstanding summary of the latest CGRP-targeted therapeutic possibilities in 
migraine. 
94. Vecsei L, Lukacs M, Tajti J, Fulop F, Toldi J, Edvinsson L. The therapeutic impact of 
new migraine discoveries. Current medicinal chemistry,  (2018). 
95. Vecsei L, Tuka B, Tajti J. Role of PACAP in migraine headaches. Brain : a journal of 
neurology, 137(Pt 3), 650-651 (2014). 
96. Tajti J, Szok D, Majlath Z, Tuka B, Csati A, Vecsei L. Migraine and neuropeptides. 
Neuropeptides, 52, 19-30 (2015). 
97. Tajti J, Pardutz A, Vamos E et al. Migraine is a neuronal disease. Journal of Neural 
Transmission, 118(4), 511-524 (2011). 
98. Tajti J, Szok D, Pardutz A et al. Where does a migraine attack originate? In the 
brainstem. Journal of Neural Transmission, 119(5), 557-568 (2012). 
99. Tajti J, Uddman R, Moller S, Sundler F, Edvinsson L. Messenger molecules and 
receptor mRNA in the human trigeminal ganglion. Journal of The Autonomic Nervous 
System, 76(2-3), 176-183 (1999). 
100. Eftekhari S, Salvatore CA, Johansson S, Chen TB, Zeng Z, Edvinsson L. Localization 
of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to 
the blood-brain barrier. Brain Research, 1600, 93-109 (2015). 
101. Edvinsson L, Villalon CM, MaassenVanDenBrink A. Basic mechanisms of migraine 
and its acute treatment. Pharmacology & Therapeutics, 136(3), 319-333 (2012). 
102. Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annual Review of 
Physiology, 75, 365-391 (2013). 
103. Edvinsson L. Headache advances in 2017: a new horizon in migraine therapy. The 
Lancet. Neurology, 17(1), 5-6 (2018). 
104. Vecsei L, Szok D, Csati A, Tajti J. CGRP antagonists and antibodies for the treatment 
of migraine. Expert Opinion on Investigational Drugs, 24(1), 31-41 (2015). 
105. Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine 
prevention: Evidence review and clinical implications. Cephalalgia, 39(3), 445-458 
(2019). 
106. Goadsby PJ. Pathophysiology of cluster headache: a trigeminal autonomic cephalgia. 
The Lancet. Neurology, 1(4), 251-257 (2002). 
107. Silberstein SD, Mechtler LL, Kudrow DB et al. Non-Invasive Vagus Nerve 
Stimulation for the ACute Treatment of Cluster Headache: Findings From the 
Randomized, Double-Blind, Sham-Controlled ACT1 Study. Headache, 56(8), 1317-
1332 (2016). 
108. Goadsby PJ, de Coo IF, Silver N et al. Non-invasive vagus nerve stimulation for the 
acute treatment of episodic and chronic cluster headache: A randomized, double-blind, 
sham-controlled ACT2 study. Cephalalgia, 38(5), 959-969 (2018). 
109. Morris J, Straube A, Diener HC et al. Cost-effectiveness analysis of non-invasive 
vagus nerve stimulation for the treatment of chronic cluster headache. The Journal of 
Headache and Pain, 17, 43 (2016). 
110. Mwamburi M, Liebler EJ, Tenaglia AT. Cost-effectiveness of gammaCore (non-
invasive vagus nerve stimulation) for acute treatment of episodic cluster headache. 
The American journal of managed care, 23(16 Suppl), S300-S306 (2017). 
111. Magis D, Bruno MA, Fumal A et al. Central modulation in cluster headache patients 
treated with occipital nerve stimulation: an FDG-PET study. BMC Neurology, 11, 25 
(2011). 
112. Matharu MS, Bartsch T, Ward N, Frackowiak RS, Weiner R, Goadsby PJ. Central 
neuromodulation in chronic migraine patients with suboccipital stimulators: a PET 
study. Brain, 127(Pt 1), 220-230 (2004). 
113. Goadsby PJ, May A. PET demonstration of hypothalamic activation in cluster 
headache. Neurology, 52(7), 1522 (1999). 
114. Wilbrink LA, Teernstra OP, Haan J et al. Occipital nerve stimulation in medically 
intractable, chronic cluster headache. The ICON study: rationale and protocol of a 
randomised trial. Cephalalgia, 33(15), 1238-1247 (2013). 
115. Brewer AC, Trentman TL, Ivancic MG et al. Long-term outcome in occipital nerve 
stimulation patients with medically intractable primary headache disorders. 
Neuromodulation, 16(6), 557-562; discussion 563-554 (2013). 
116. Leone M, Proietti Cecchini A, Messina G, Franzini A. Long-term occipital nerve 
stimulation for drug-resistant chronic cluster headache. Cephalalgia,  37(8), 756-763 
(2017). 
117. Mueller O, Diener HC, Dammann P et al. Occipital nerve stimulation for intractable 
chronic cluster headache or migraine: a critical analysis of direct treatment costs and 
complications. Cephalalgia, 33(16), 1283-1291 (2013). 
118. Lainez MJ, Guillamon E. Cluster headache and other TACs: Pathophysiology and 
neurostimulation options. Headache, 57(2), 327-335 (2017). 
119. Fontaine D, Blond S, Lucas C et al. Occipital nerve stimulation improves the quality 
of life in medically-intractable chronic cluster headache: Results of an observational 
prospective study. Cephalalgia, 37(12), 1173-1179 (2017). 
120. Leone M, Giustiniani A, Cecchini AP. Cluster headache: present and future therapy. 
Neurological Sciences, 38(Suppl 1), 45-50 (2017). 
121. Cadalso RT, Jr., Daugherty J, Holmes C, Ram S, Enciso R. Efficacy of Electrical 
Stimulation of the Occipital Nerve in Intractable Primary Headache Disorders: A 
Systematic Review with Meta-Analyses. Journal of Oral & Facial Pain and 
Headache, 32(1), 40-52). 
* This review provides an overview of the current data of occipital nerve stimulation in 
pharmacoresistant primary headaches. 
122. Barloese MC, Jurgens TP, May A et al. Cluster headache attack remission with 
sphenopalatine ganglion stimulation: experiences in chronic cluster headache patients 
through 24 months. The Journal of Headache and Pain, 17(1), 67 (2016). 
123. Ho KWD, Przkora R, Kumar S. Sphenopalatine ganglion: block, radiofrequency 
ablation and neurostimulation - a systematic review. The Journal of Headache and 
Pain, 18(1), 118 (2017). 
* An excellent overview of the blockade and electrical stimulation of the sphenopalatine 
ganglion. 
124. Robbins MS, Robertson CE, Kaplan E et al. The Sphenopalatine Ganglion: Anatomy, 
Pathophysiology, and Therapeutic Targeting in Headache. Headache, 56(2), 240-258 
(2016). 
125. Schoenen J, Jensen RH, Lanteri-Minet M et al. Stimulation of the sphenopalatine 
ganglion (SPG) for cluster headache treatment. Pathway CH-1: a randomized, sham-
controlled study. Cephalalgia , 33(10), 816-830 (2013). 
126. Jurgens TP, Barloese M, May A et al. Long-term effectiveness of sphenopalatine 
ganglion stimulation for cluster headache. Cephalalgia, 37(5), 423-434 (2017). 
127. Barloese M, Petersen A, Stude P, Jurgens T, Jensen RH, May A. Sphenopalatine 
ganglion stimulation for cluster headache, results from a large, open-label European 
registry. The Journal of Headache and Pain, 19(1), 6 (2018). 
128. Ambrosini A, Vandenheede M, Rossi P et al. Suboccipital injection with a mixture of 
rapid- and long-acting steroids in cluster headache: a double-blind placebo-controlled 
study. Pain, 118(1-2), 92-96 (2005). 
129. Rozen TD. High-Volume Anesthetic Suboccipital Nerve Blocks for Treatment 
Refractory Chronic Cluster Headache With Long-Term Efficacy Data: An 
Observational Case Series Study. Headache,  (2018). 
130. Lambru G, Abu Bakar N, Stahlhut L et al. Greater occipital nerve blocks in chronic 
cluster headache: a prospective open-label study. European Journal of Neurology, 
21(2), 338-343 (2014). 
131. Wei J, Robbins MS. Greater Occipital Nerve Injection versus Oral Steroids for Short 
Term Prophylaxis of Cluster Headache: A Retrospective Comparative Study. 
Headache, 58(6), 852-858 (2018). 
132. Gantenbein AR, Lutz NJ, Riederer F, Sandor PS. Efficacy and safety of 121 injections 
of the greater occipital nerve in episodic and chronic cluster headache. Cephalalgia, 
32(8), 630-634 (2012). 
133. Gaul C, Roguski J, Dresler T et al. Efficacy and safety of a single occipital nerve 
blockade in episodic and chronic cluster headache: A prospective observational study. 
Cephalalgia, 37(9), 873-880 (2017). 
134. Leroux E, Valade D, Taifas I et al. Suboccipital steroid injections for transitional 
treatment of patients with more than two cluster headache attacks per day: a 
randomised, double-blind, placebo-controlled trial. The Lancet. Neurology, 10(10), 
891-897 (2011). 
135. Martelletti P, Giamberardino MA, Mitsikostas DD. Greater occipital nerve as target 
for refractory chronic headaches: from corticosteroid block to invasive 
neurostimulation and back. Expert Review of Neurotherapeutics, 16(8), 865-866 
(2016). 
136. Fang L, Jingjing L, Ying S, Lan M, Tao W, Nan J. Computerized tomography-guided 
sphenopalatine ganglion pulsed radiofrequency treatment in 16 patients with refractory 
cluster headaches: Twelve- to 30-month follow-up evaluations. Cephalalgia, 36(2), 
106-112 (2016). 
137. Bendersky DC, Hem SM, Yampolsky CG. Unsuccessful pulsed radiofrequency of the 
sphenopalatine ganglion in patients with chronic cluster headache and subsequent 
successful thermocoagulation. Pain Practice, 15(5), E40-45 (2015). 
138. Bratbak DF, Nordgard S, Stovner LJ et al. Pilot study of sphenopalatine injection of 
onabotulinumtoxinA for the treatment of intractable chronic cluster headache. 
Cephalalgia, 36(6), 503-509 (2016). 
139. Kastler A, Cadel G, Comte A et al. Alcohol percutaneous neurolysis of the 
sphenopalatine ganglion in the management of refractory cranio-facial pain. 
Neuroradiology, 56(7), 589-596 (2014). 
140. Sostak P, Krause P, Forderreuther S, Reinisch V, Straube A. Botulinum toxin type-A 
therapy in cluster headache: an open study. The Journal of Headache and Pain, 8(4), 
236-241 (2007). 
141. Lampl C, Rudolph M, Brautigam E. OnabotulinumtoxinA in the treatment of 
refractory chronic cluster headache. The Journal of Headache and Pain, 19(1), 45 
(2018). 
142. Trimboli M, Al-Kaisy A, Andreou AP, Murphy M, Lambru G. Non-invasive vagus 
nerve stimulation for the management of refractory primary chronic headaches: A 
real-world experience. Cephalalgia, 38(7), 1276-1285 (2018). 
143. Tso AR, Marin J, Goadsby PJ. Noninvasive Vagus Nerve Stimulation for Treatment 
of Indomethacin-Sensitive Headaches. JAMA Neurology, 74(10), 1266-1267 (2017). 
144. Lambru G, Matharu MS. SUNCT and SUNA: medical and surgical treatments. 
Neurological Sciences, 34 Suppl 1, S75-81 (2013). 
145. Arca KN, Halker Singh RB. SUNCT and SUNA: an Update and Review. Current 
Pain and Headache Reports, 22(8), 56 (2018). 
146. Lambru G, Shanahan P, Watkins L, Matharu MS. Occipital nerve stimulation in the 
treatment of medically intractable SUNCT and SUNA. Pain Physician, 17(1), 29-41 
(2014). 
147. Miller S, Watkins L, Matharu MS. Treatment of intractable hemicrania continua by 
occipital nerve stimulation. Journal of Neurology, Neurosurgery, and Psychiatry, 
88(9), 805-806 (2017). 
148. Baraldi C, Pellesi L, Guerzoni S, Cainazzo MM, Pini LA. Therapeutical approaches to 
paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform 
headache attacks: a critical appraisal. The Journal of Headache and Pain, 18(1), 71 
(2017). 
149. Guerrero AL, Herrero-Velazquez S, Penas ML et al. Peripheral nerve blocks: a 
therapeutic alternative for hemicrania continua. Cephalalgia, 32(6), 505-508 (2012). 
150. Androulakis XM, Krebs KA, Ashkenazi A. Hemicrania continua may respond to 
repetitive sphenopalatine ganglion block: A case report. Headache, 56(3), 573-579 
(2016). 
151. Tfelt-Hansen P, Olesen J. Taking the negative view of current migraine treatments: the 
unmet needs. CNS Drugs, 26(5), 375-382 (2012). 
152. Miller S, Matharu MS. Migraine is underdiagnosed and undertreated. The 
Practitioner, 258(1774), 19-24, 12-13 (2014). 
153. Tajti J, Tuka B, Botz B, Helyes Z, Vecsei L. Role of pituitary adenylate cyclase-
activating polypeptide in nociception and migraine. CNS & Neurological Disorders 
Drug Targets, 14(4), 540-553 (2015). 
154. Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M. PACAP38 induces 
migraine-like attacks in patients with migraine without aura. Brain, 132(Pt 1), 16-25 
(2009). 
155. Tuka B, Helyes Z, Markovics A et al. Alterations in PACAP-38-like 
immunoreactivity in the plasma during ictal and interictal periods of migraine patients. 
Cephalalgia, 33(13), 1085-1095 (2013). 
156. Tuka B, Szabo N, Toth E et al. Release of PACAP-38 in episodic cluster headache 
patients - an exploratory study. The Journal of Headache and Pain, 17(1), 69 (2016). 
157. Rubio-Beltran E, Correnti E, Deen M et al. PACAP38 and PAC1 receptor blockade: a 
new target for headache? The Journal of Headache and Pain, 19(1), 64 (2018). 
158. Guo S, Vecsei L, Ashina M. The L-kynurenine signalling pathway in trigeminal pain 
processing: a potential therapeutic target in migraine? Cephalalgia, 31(9), 1029-1038 
(2011). 
159. Curto M, Lionetto L, Fazio F, Mitsikostas DD, Martelletti P. Fathoming the 
kynurenine pathway in migraine: why understanding the enzymatic cascades is still 
critically important. Internal and Emergency Medicine, 10(4), 413-421 (2015). 
160. Vecsei L, Szalardy L, Fulop F, Toldi J. Kynurenines in the CNS: recent advances and 
new questions. Nature Reviews. Drug Discovery, 12(1), 64-82 (2013). 
161. Tajti J, Majlath Z, Szok D et al. Novel kynurenic acid analogues in the treatment of 
migraine and neurodegenerative disorders: preclinical studies and pharmaceutical 
design. Current Pharmaceutical Design, 21(17), 2250-2258 (2015). 
162. Tajti J, Szok D, Nagy-Grocz G et al. Kynurenines and PACAP in Migraine: Medicinal 
Chemistry and Pathogenetic Aspects. Current Medicinal Chemistry, 24(13), 1332-
1349 (2017). 
163. Kortesi T, Tuka B, Tajti J et al. Kynurenic Acid Inhibits the Electrical Stimulation 
Induced Elevated Pituitary Adenylate Cyclase-Activating Polypeptide Expression in 
the TNC. Frontiers in Neurology, 8, 745 (2017). 
164. Curto M, Lionetto L, Negro A et al. Altered kynurenine pathway metabolites in serum 
of chronic migraine patients. The Journal of Headache and pain, 17, 47 (2015). 
165. Cohen SP, Peterlin BL, Fulton L et al. Randomized, double-blind, comparative-
effectiveness study comparing pulsed radiofrequency to steroid injections for occipital 
neuralgia or migraine with occipital nerve tenderness. Pain, 156(12), 2585-2594 
(2015). 
 
